Tissue or cell type identification using epigenetic profiling in cfdna samples

The enzymatic 'unmethylome' profiling technique addresses the limitations of existing cfDNA analysis methods by tagging unmodified nucleotides for unbiased sequencing, enabling accurate identification of tissue or cell types in cfDNA samples, particularly at low concentrations, and is suitable for diagnostic applications.

WO2026239115A1PCT designated stage Publication Date: 2026-11-19TAGOMICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2026/050842
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current methods for analyzing cell-free DNA (cfDNA) in liquid biopsies are limited by DNA degradation during bisulfite treatment, low conversion efficiencies in bisulfite-free approaches, and biased representation of genomic loci in enrichment-based methods, making it difficult to accurately identify the cellular origin of cfDNA, especially at low concentrations.

Method used

An enzymatic 'unmethylome' profiling technique that uses a methyltransferase to tag unmodified nucleotides, allowing for unbiased DNA library preparation and sequencing, enabling the detection of characteristic epigenetic modification patterns in cfDNA samples without bisulfite conversion, and suitable for low DNA quantities.

Benefits of technology

The method provides a reproducible and cost-effective way to identify specific tissues or cell types in cfDNA samples, compatible with single-cell analysis, and can be integrated with standard sequencing platforms for diagnostic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GB2026050842_19112026_PF_FP_ABST
    Figure GB2026050842_19112026_PF_FP_ABST
Patent Text Reader

Abstract

A method for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample is disclosed. The method involves using a methyltransferase to apply a tag to unmodified nucleotide residues in the sample.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Identification Method

[0002] Field

[0003] The present application relates to methods for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample.

[0004] Introduction

[0005] Advances in sequencing technologies have facilitated personalized clinical diagnosis.

[0006] Liquid biopsy is a minimally invasive diagnostic technique that involves the analysis of various components present in bodily fluids, and cell-free DNA (cfDNA) has become an important focus in liquid biopsy applications. Disease diagnoses may be made using cfDNA, which exploits the fact that cell death and necrotic processes may cause DNA to be released into bodily fluids including circulating blood and urine.

[0007] Adverse side effects often account for the failure of drug clinical trials. The causes of adverse side effects for drugs are multifactorial but include the biodistribution of drugs to unintended tissues, and assessing the toxicity of therapeutic agents to untargeted tissues remains a major challenge in drug development and drug safety research.

[0008] Various technologies have been developed to detect and analyse cfDNA in bodily fluid samples. Accurately determining the cellular origin of cfDNA, however, remains a significant challenge, particularly at the very low DNA concentrations that may be present in body fluid samples. This is an essential problem in non-invasive diagnosis.

[0009] While liquid biopsies initially emphasized the detection of genetic markers in cfDNA, recent studies have unveiled the important insights that may also be made through non-genetic features. In contrast to genetic alterations, which can be relatively rare and hard to predict, epigenetic modifications occur more frequently. Unlike the genetic code, the epigenome differs between cell and tissue type, and in response to different physiological and environmental stimuli. Epigenetic modifications are involved in cell type-specific modulation and adaptation of genome programming to control a diverse range of cellular functions. Thus, different tissues and cell types have different epigenetic modification patterns and the detection of epigenetic modifications in cfDNA may indicate the tissue of origin. By analysing the epigenetic modification patterns and other features of cfDNA, the tissues contributing to the cfDNA pool in an individual may be identified and distinguished.

[0010] However, current methods for studying epigenetic modifications fundamentally limit the scope of cfDNA analysis and associated non-invasive diagnostic approaches.

[0011] Methods comprising bisulfite conversion of cytosine to uracil may be used for epigenetic analysis, but the treatment of DNA with bisulfite can lead to DNA degradation. This limits the application of bisulfite in samples where the DNA quantity is low, as is typical for circulating cell-free DNA (cfDNA) in blood.

[0012] Bisulfite-free approaches have been demonstrated that employ pyridine borane base conversion or enzymatic deamination of unmethylated cytosine. However, such approaches can suffer from low conversion efficiencies, relative to bisulfite conversion, and are inherently focussed on the analysis of individual cytosine bases, necessitating (comparative) whole-genome sequencing for biomarker discovery. This invariably leads to reduction of the test to a panel of genomic loci for application in the clinic, which effectively limits the diagnosis to a population that is similar to that profiled during the biomarker discovery phase of the test development.

[0013] Enrichment-based approaches for epigenetic profiling allow cost-effective, whole genome profiling that is more suited to the challenges of delivering personalised medicine. Until recently, the amount of available cfDNA in a blood sample limited the application of either antibodies (“methyl-DNA Immunoprecipitation”, also referred to as “MeDIP-Seq”) or methyl-binding domain protein (referred to as “MBD-Seq”) in the analysis of cfDNA. A further limitation of approaches involving MeDIP-Seq or MBD-Seq is that these proteins preferentially bind heavily methylated regions of the genome, which leads to an over-representation of these loci in the sequencing experiment.

[0014] There is, therefore, a need for improved epigenetic profiling methods, that are capable of profiling small quantities of DNA, such as may be obtained from liquid biopsy (e.g. peripheral blood) samples, that are capable of application to large portions of the genome without bias arising from differences in sequence, such as CpG density, and that may be applied cost effectively at large scales for use as diagnostic tools and to inform personalised medicine approaches.

[0015] The inventors have developed an epigenetic profiling technique which meets these requirements and overcomes various limitations of existing methods, including thosediscussed above. The disclosed method is based on an enzymatic “unmethylome” profiling approach, in which unmodified nucleotides, such as unmodified CpG dinucleotides, in a DNA sample are derivatised in such a way that they can then be isolated without bias and subsequently sequenced. The disclosed technique is an advantageously simple process that can be performed in a one-pot approach, that can be integrated readily with standard high throughput sequencing platforms, and may be used with lower quantities of input DNA than has previously been possible.

[0016] The disclosed method combines a procedure of DNA library preparation for next generation sequencing and a method for labelling unmodified, such as epigenetically unmodified, nucleotides. Using the label, the DNA library is subsequently fractionated into modified and unmodified fractions. The method advantageously minimises the number of DNA purification steps required and is highly efficient. As a result, the disclosed enzymatic platform can be applied at DNA concentrations that are compatible with single-cell analysis (picogram inputs). The approach has been found to be highly reproducible and unbiased, and may be used as a platform for the diagnosis of disease and the identification of DNA from a specific tissue or cell type in a cfDNA sample.

[0017] Hence, in a first aspect, there is provided a method for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample from a subject, the method comprising:

[0018] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in the sample, wherein each unmodified nucleotide residue is unmodified in the target position;

[0019] (2) inactivating the methyltransferase;

[0020] (3) preparing the sample into a sequencing library;

[0021] (4) binding an affinity label to each tag;

[0022] (5) fractionating the sequencing library to obtain a first fraction and a second fraction, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0023] (6) sequencing the polynucleotides of the first and / or second fraction to obtain the modification status of nucleotide residues in a target marker region of the polynucleotide sequence,

[0024] wherein the target marker region of the polynucleotide sequence is a region that has a characteristic epigenetic modification pattern in the specific tissue or cell type that is indicative of the specific tissue or cell type, and

[0025] wherein the detection of the characteristic epigenetic modification pattern in the modification status information identifies DNA from the specific tissue or cell type in the sample.

[0026] In some embodiments, the method may comprise a method for determining the presence of DNA from the specific tissue or cell type in the sample, wherein the detection of the characteristic epigenetic modification pattern in the modification status information indicates the presence in the sample of DNA from the specific tissue or cell type.

[0027] As used herein, unless otherwise stated, the term “marker region” and similar terms, refers to a genomic region that has an epigenetic modification pattern that is characteristic of a specific tissue or cell type. For example, a marker region may have an epigenetic modification pattern that is unique to a particular tissue or cell type. Marker regions have been described, for example, by Loyfer et al. (Nature. 613: 355-364).

[0028] As used herein, unless otherwise stated, the term “target marker region” and similar terms, refers to a marker region that has an epigenetic modification pattern that is preselected for use in the method on the basis of being characteristic, such as uniquely characteristic, for the specific tissue or cell type that is the origin of the DNA to be detected.

[0029] In some embodiments, a characteristic epigenetic modification pattern for a specific tissue or cell type for use in the disclosed method may be identified by a method comprising:

[0030] (A) obtaining a first unmethylome profile of enriched unmethylated DNA from a first tissue or cell type using a method comprising:

[0031] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in a DNA sample from the first tissue or cell type, wherein each unmodified nucleotide residue is unmodified in the target position;

[0032] (2) inactivating the methyltransferase;

[0033] (3) preparing the sample into a sequencing library;

[0034] (4) binding an affinity label to each tag;

[0035] (5) fractionating the sequencing library to obtain a first fraction and a second fraction, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0036] (6) sequencing the polynucleotides of the first fraction to obtain the first unmethylome profile of enriched unmethylated DNA;

[0037] (B) obtaining a second unmethylome profile of enriched unmethylated DNA from a second tissue or cell type, that is different to the first tissue or cell type, using the method used to obtain the first unmethylome profile;

[0038] (C) comparing the first unmethylome profile to the second unmethylome profile to identify a discriminatory region in which the first unmethylome profile is different to the second unmethylome profile, and

[0039] (D) identifying the methylation profile of the discriminatory region of the first unmethylome profile as a characteristic epigenetic modification pattern of the first tissue or cell type.

[0040] Thus, in some embodiments, there is provided a method for identifying a characteristic epigenetic modification pattern for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample from a subject.

[0041] In some embodiments, the method for identifying a characteristic epigenetic modification pattern may further comprise repeating step (B) to obtain a third unmethylome profile of enriched unmethylated DNA from a third tissue or cell type, wherein the third tissue or cell type is different to either of the first or second tissue or cell types, and in step (C) comparing the first unmethylome profile to the second and third unmethylome profiles to identify a discriminatory region in which the first unmethylome profile is different to the second and third unmethylome profiles.

[0042] In some embodiments, the method for identifying a characteristic epigenetic modification pattern may further comprise repeating step (B) to obtain a plurality of further unmethylome profiles of enriched unmethylated DNA from a plurality of further tissue or cell types, wherein each of the plurality of tissue or cell types is different, and is also different to the first or second tissue or cell type, and in step (C) comparing the first unmethylome profile to the second and further plurality of unmethylome profiles to identify a discriminatory region in which the first

[0043] unmethylome profile is different to the second and further plurality of unmethylome profiles.

[0044] Thus, in some embodiments, the method for identifying a characteristic epigenetic modification pattern of a tissue or cell type may comprise:

[0045] (A) obtaining a first unmethylome profile of enriched unmethylated DNA from a first tissue or cell type using a method comprising:

[0046] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in a DNA sample from the first tissue or cell type, wherein each unmodified nucleotide residue is unmodified in the target position;

[0047] (2) inactivating the methyltransferase;

[0048] (3) preparing the sample into a sequencing library;

[0049] (4) binding an affinity label to each tag;

[0050] (5) fractionating the sequencing library to obtain a first fraction and a second fraction, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0051] (6) sequencing the polynucleotides of the first fraction to obtain the first unmethylome profile of enriched unmethylated DNA;

[0052] (B) obtaining further unmethylome profiles of enriched unmethylated DNA from each of a plurality of tissue or cell types, using the method used to obtain the first unmethylome profile, wherein each of the plurality of tissue or cell types is different, and is also different to the first tissue or cell type;

[0053] (C) comparing the first unmethylome profile to the further unmethylome profiles to identify a discriminatory region in which the first unmethylome profile is different to each of the further plurality of unmethylome profiles, and

[0054] (D) identifying the methylation profile of the discriminatory region of the first unmethylome profile as a characteristic epigenetic modification pattern of the first tissue or cell type.

[0055] In some embodiments, there is provided a method for producing an atlas of characteristic epigenetic modification patterns for use in the identification or detection of DNA from a specific tissue or cell type. The atlas may also be used for identifying the tissue of origin of DNA in a DNA sample. The method for producing an atlas may

[0056] comprise the use of the disclosed method to identify characteristic epigenetic modification patterns for each of a plurality of different tissue or cell types.

[0057] Thus, in some embodiments, the method for producing an atlas of characteristic epigenetic modification patterns may comprise:

[0058] (A) obtaining one or more unmethylome profiles of enriched unmethylated DNA from each of a plurality of different tissue or cell types using, to obtain each unmethylome profile, a method comprising:

[0059] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in a DNA sample from the tissue or cell type, wherein each unmodified nucleotide residue is unmodified in the target position;

[0060] (2) inactivating the methyltransferase;

[0061] (3) preparing the sample into a sequencing library;

[0062] (4) binding an affinity label to each tag;

[0063] (5) fractionating the sequencing library to obtain a first fraction and a second fraction, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0064] (6) sequencing the polynucleotides of the first fraction to obtain the unmethylome profile of enriched unmethylated DNA;

[0065] (B) comparing each unmethylome profile to an unmethylome profile from each of a plurality of the different tissue or cell types to identify one or more discriminatory regions for each unmethylome profile in which the unmethylome profile is uniquely different to the other unmethylome profiles, and

[0066] (D) identifying each of the one or more discriminatory regions for each unmethylome profile as a characteristic epigenetic modification pattern of the tissue or cell type from which the profile is obtained.

[0067] In any of the disclosed embodiments, one or more of the unmethylome profiles may have been previously obtained and the disclosed methods may be understood as being performed using the previously obtained unmethylome profiles. Thus, as used herein, unless otherwise stated, methods that are indicated to include the step or steps of “obtaining an unmethylome profile”, “obtaining unmethylome profiles”, “obtaining a profile”, “obtaining profiles” and similar terms, encompass both methods in which the step or steps are performed and the profiles obtained, and also methods in which thestep or steps have previously been performed and the method is performed using the previously obtained profiles.

[0068] In some embodiments of any of the disclosed methods, the marker region may be a single nucleotide. In some embodiments, the marker region may comprise a plurality of nucleotides. In some embodiments, the marker region may be a single dinucleotide, which may be a CpG dinucleotide, and in such embodiments, the epigenetic modification pattern of the marker region may be the methylation status of the cytosine C5 position of the CpG dinucleotide.

[0069] In some embodiments, the marker region may be a single sequence of contiguous nucleotides, in which some or all of the nucleotides may be subject to epigenetic modification.

[0070] In some embodiments, the marker region may be a single CpG dinucleotide.

[0071] In some embodiments, the marker region may comprise a plurality of CpG dinucleotides. In some embodiments, the marker region may comprise 1-120 CpG dinucleotides.

[0072] In some embodiments, the marker region may comprise a plurality of contiguous CpG dinucleotides.

[0073] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 20-5000bp.

[0074] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 40-4500bp.

[0075] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 60-4000bp.

[0076] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 80-3000bp.

[0077] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 100-2000bp.

[0078] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 120-1000bp.

[0079] In some embodiments, the marker region may be a single sequence of contiguous nucleotides comprising a CpG dinucleotide or a plurality of CpG dinucleotides. In some embodiments, the sequence of contiguous nucleotides may have a size of 120-4600bp.

[0080] In some embodiments, the marker region may comprise a plurality of separate sequences of contiguous nucleotides, each separate sequence of contiguous nucleotides being located in a separate region of the subject’s genome. In some embodiments, each separate sequence of contiguous nucleotides of the marker region may have a size listed above, such as a size of 120-4600bp.

[0081] In some embodiments, the marker region may comprise a plurality of sequences of contiguous nucleotides, each of which may contain one or a plurality of CpG dinucleotides, each sequence of contiguous nucleotides being located in a separate region of the subject’s genome.

[0082] A surprising and unexpected advantage of the disclosed method is that marker regions have been identified using, and found to be suitable for use in, the disclosed method, containing a single CpG dinucleotide, or comprising a plurality of separate regions, one or more of which contains a single CpG dinucleotide. Marker regions containing a single CpG dinucleotide in isolation have been difficult to identify using previous methods such as base conversion.

[0083] In some embodiments, the marker region may comprise a CpG site density of 0.0022-0.05 sites / bp.

[0084] In some embodiments, the marker region may be, or may comprise, a region of high CpG density. In some embodiments, the marker region may be, or may comprise, a plurality of regions of high CpG density. In such embodiments, the plurality of regions of high CpG density may each be located in a separate region of the subject’s genome.

[0085] In some embodiments, the method may comprise the detection of a plurality of marker regions. For example, in some embodiments, the method may comprise the detection of 2-500,000 marker regions. In some preferred embodiments, the method may comprise the detection of 10-400,000 marker regions, such as 25-300,000 marker regions, 50- 200,000 marker regions, or 75-150,000 marker regions. Typically, the method may comprise the detection of 100-100,000 marker regions.

[0086] As used herein, unless otherwise stated, the term “epigenetic modification pattern” and similar terms, refers to the modification status of the nucleotide or nucleotides in the marker region, and in particular, the modification status of the nucleotide or nucleotides in the marker region that are subject to epigenetic modification. Thus, the epigenetic modification pattern includes the methylation status of the cytosine C5 position of each CpG dinucleotide in the marker region.

[0087] In embodiments in which the marker region is or contains a single CpG dinucleotide, the epigenetic modification pattern of the dinucleotide is binary, being either epigenetically modified or epigenetically unmodified in the cytosine C5 position of the CpG dinucleotide. In embodiments in which the marker region comprises a plurality of CpG dinucleotides, the epigenetic modification pattern is the epigenetic modification status of the cytosine C5 position of each of the CpG dinucleotides in the marker region.

[0088] Typically, the epigenetic modification pattern of a marker region for a specific tissue or cell type comprises an increased proportion of epigenetically unmodified nucleotides relative to the proportion present in the same marker region from a different tissue or cell type. Indeed, the epigenetic modification pattern of a marker region for a specific tissue or cell type typically comprises an increased proportion of epigenetically unmodified nucleotides relative to the proportion present in the same marker region in any other tissue or cell type.

[0089] In some embodiments, the epigenetic modification pattern of the marker region may be epigenetically unmodified. In some embodiments, the epigenetic modification pattern of the marker region may be substantially epigenetically unmodified.

[0090] Unless otherwise stated, the term “the percentage of the epigenetic modification pattern” that is epigenetically modified or unmodified, and similar terms, refers to the proportion of nucleotides in the marker region that are epigenetically modified or unmodified relative to the total number of nucleotides in the marker region that may be subject to epigenetic modification. Thus, an epigenetic modification pattern in which 9 out of 10 CpG sites are unmodified in the cytosine C5 position may be described as being 90% unmodified.

[0091] In some embodiments, the epigenetic modification pattern of the marker region may be at least 90%, such as at least 95%, or at least 99% epigenetically unmodified.

[0092] In some embodiments, the marker region may be, or may comprise, a region of high CpG density, and the epigenetic modification pattern of the marker region may be at least 90%, such as at least 95%, or at least 99% epigenetically unmodified.

[0093] In some embodiments, the marker region may be, or may comprise, a plurality of regions of high CpG density, and the epigenetic modification pattern of the marker region may be at least 90%, such as at least 95%, or at least 99% epigenetically unmodified.

[0094] In such embodiments, the plurality of regions of high CpG density may each be located in a separate region of the subject’s genome, and the epigenetic modification pattern of the marker region may be at least 90%, such as at least 95%, or at least 99% epigenetically unmodified.

[0095] As used herein, unless otherwise stated, the terms “identifying DNA from a specific tissue or cell type” and similar terms, encompass determining the presence of DNA from the specific tissue or cell type, determining the absence of DNA from the specific tissue or cell type, and determining the level of DNA from the specific tissue or cell type-

[0096] Thus, in some embodiments, the method may be a method for determining the absence of DNA from a specific tissue or cell type in a cfDNA sample from a subject.

[0097] In some embodiments, the method may be a method for determining the level of DNA from a specific tissue or cell type in a cfDNA sample from a subject.

[0098] In some embodiments, the method may be a method for quantifying the level of DNA from a specific tissue or cell type in a cfDNA sample from a subject.

[0099] As used herein, unless otherwise stated, the term “the level of DNA” and similar terms, may refer to the absolute or relative level as indicated. For example, in some embodiments, the level of DNA may refer to the concentration of DNA from a specific tissue or cell type in the cfDNA sample, measured in standard units such as picograms per milliliter (pg / ml). In some embodiments, the level of DNA may refer to the level relative to the level in a different cfDNA sample, such as a control sample. In some embodiments, the level of DNA may refer to the level relative to the total amount of DNA in the cfDNA sample, i.e. the proportion of DNA in the sample that originates in the specific tissue or cell type of interest. The level of DNA from a specific tissue or cell type may be determined or quantified based on level of input DNA.

[0100] The identification of DNA from a specific tissue or cell type in a cfDNA sample from a subject may indicate the presence of cell death in the specific tissue or cell type in the subject. Thus, in some embodiments, the method may be a method for identifying, in a cfDNA sample from a subject, cell death in a specific tissue or cell type of the subject, the method comprising:

[0101] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in the sample, wherein each unmodified nucleotide residue is unmodified in the target position;

[0102] (2) inactivating the methyltransferase;

[0103] (3) preparing the sample into a sequencing library;

[0104] (4) binding an affinity label to each tag;

[0105] (5) fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0106] (6) sequencing the polynucleotides of the first and / or second fraction to obtain the modification status of nucleotide residues in a target marker region of the polynucleotide sequence,

[0107] wherein the target marker region of the polynucleotide sequence is a region that has a characteristic epigenetic modification pattern in the specific tissue or cell type that is indicative of the specific tissue or cell type, and

[0108] wherein the detection of the characteristic epigenetic modification pattern in the modification status information identifies the presence of cell death in the specific tissue or cell type.

[0109] The identification of DNA from a specific tissue or cell type in a cfDNA sample from a subject may indicate that an active agent that has been administered to the subject is toxic to the specific tissue or cell type. Thus, in some embodiments, the method may be a method for identifying, in a cfDNA sample from a subject, cell death of a specific tissue or cell type in response to an active agent that has been administered to the subject, the method comprising:

[0110] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in the sample, wherein each unmodified nucleotide residue is unmodified in the sample;

[0111] (2) inactivating the methyltransferase;

[0112] (3) preparing the sample into a sequencing library;

[0113] (4) binding an affinity label to each tag;

[0114] (5) fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0115] (6) sequencing the polynucleotides of the first and / or second fraction to obtain the modification status of nucleotide residues in a target marker region of the polynucleotide sequence,

[0116] wherein the target marker region of the polynucleotide sequence is a region that has a characteristic epigenetic modification pattern in the specific tissue or cell type that is indicative of the specific tissue or cell type, and

[0117] wherein the detection of the characteristic epigenetic modification pattern in the modification status information identifies the presence of cell death in the specific tissue or cell type induced by the active agent.

[0118] As used herein, unless otherwise stated, the term “active agent” refers to any compound or molecule, such as an active pharmaceutical ingredient, that may be biologically active or may have any other direct effect on the body.

[0119] In some embodiments, the epigenetic modification pattern that is indicative of the specific tissue or cell type may comprise epigenetically unmodified nucleotide residues.

[0120] In some embodiments, the method may comprise sequencing the polynucleotides of the first fraction. In some embodiments, the method may comprise sequencing the polynucleotides of the first fraction only.

[0121] In some embodiments, the method may comprise sequencing the polynucleotides of the first fraction, and using the sequencing information to determine the modification status of nucleotide residues in the polynucleotide sample.

[0122] In some embodiments, obtaining the modification status of nucleotide residues in a target marker region of the polynucleotide sequence may comprise obtaining a profile of the modification status of nucleotide residues in a target marker region of the polynucleotide sequence. Obtaining a profile of the modification status of nucleotide residues in a target marker region of the polynucleotide sequence may comprise comparing the sequences of the sequencing reads of the first and / or second fraction to a reference sequence comprising the target marker region to determine the location of the sequencing reads within the reference sequence and thereby the presence or otherwise of unmodified nucleotide residues at specific locations within the target marker region.

[0123] In some embodiments, the detection of the characteristic epigenetic modification pattern in the modification status information is indicative of cell death of the identified tissue or cell type in the subject.

[0124] In some embodiments, the method may comprise obtaining the modification status of nucleotide residues in a plurality of target marker regions of the polynucleotide sequence. In such embodiments:

[0125] (a) the detection of the characteristic epigenetic modification pattern of a specific marker region in the modification status information may identify DNA in the sample from a specific tissue or cell type identified by the specific marker region; or

[0126] (b) the detection of the characteristic epigenetic modification patterns of a plurality of marker regions in the modification status information may identify DNA in the sample from the plurality of specific tissues and / or cell types identified by the specific marker regions.

[0127] In some embodiments, the method may comprise obtaining the modification status of nucleotide residues in a plurality of target marker regions of the polynucleotide sequence. In such embodiments:

[0128] (a) the detection of a significant change in the epigenetic modification pattern in a specific marker region, relative to a pre-defined level, may indicate the presence in the sample of DNA from the specific tissue or cell type identified by the specific marker region; or

[0129] (b) the detection of a significant change in the epigenetic modification patterns in a plurality of specific marker regions, relative to pre-defined levels, may indicate the presence in the sample of DNA from the plurality of specific tissues and / or cell types identified by the specific marker regions.

[0130] In some embodiments, the method may comprise obtaining the modification status of nucleotide residues in a plurality of target marker regions of the polynucleotide sequence. In such embodiments:

[0131] (a) the detection of the characteristic epigenetic modification pattern of a specific marker region in the modification status information may indicate the presence of cell death in the specific tissue or cell type identified by the specific marker region; or

[0132] (b) the detection of the characteristic epigenetic modification patterns of a plurality of marker regions in the modification status information may indicate the presence of cell death in the plurality of specific tissues and / or cell types identified by the specific marker regions.

[0133] In some embodiments, the method may comprise obtaining the modification status of nucleotide residues in a plurality of target marker regions of the polynucleotide sequence. In such embodiments:

[0134] (a) the detection of a significant change in the epigenetic modification pattern in a specific marker region, relative to a pre-defined level, may indicate the presence of cell death in the specific tissue or cell type identified by the marker region; or

[0135] (b) the detection of a significant change in the epigenetic modification patterns in a plurality of specific marker regions, relative to pre-defined levels, may indicate thepresence of cell death in the plurality of specific tissues and / or cell types identified by the specific marker regions.

[0136] In some embodiments, the method may be a method for detecting cell death in response to a specific active agent administered to the subject. In some such embodiments, the method may further comprise comparing the level of cell death in a first cfDNA sample obtained from the individual at a first time point with the level of cell death in a second cfDNA sample obtained at a second time point.

[0137] In such embodiments:

[0138] (a) the first time point may be before the administration of the active agent to the subject and the second time point may be after the administration of the active agent;

[0139] (b) the first and second time points may be after the administration of the active agent; or

[0140] (c) the first time point may be after a first administration of the active agent to the subject and the second time point may be after a second administration of the active agent.

[0141] As used herein, unless otherwise stated, the terms “fractionated”, “fractionating”, “fractionation”, and similar terms, in relation to the sequencing library refer to the separation of the polynucleotides of the sequencing library into different groups or “fractions” on the basis of the presence or absence of one or more specific features. In particular, polynucleotides may be fractionated based on the presence or absence of an associated affinity label, thereby forming a first fraction that is enriched for polynucleotides comprising an affinity label and a second fraction that is enriched for polynucleotides that do not comprise an affinity label. As such, the fractionation of the polynucleotides may also be described and / or referred to as “enriching” and / or “enrichment” of the sequencing library for polynucleotides having or not having the one or more specific features. For example, a fraction of polynucleotides may be referred to as being “enriched” for labelled or unlabelled polynucleotides, as appropriate.

[0142] As used herein, unless otherwise stated, the terms “site-specific”, “site-specifically”, and similar terms, refer to the application of a tag to a target atom within a nucleotide residue having a particular configuration. In some embodiments, the particular configuration may be the absence of a specific modification, such as a cytosine that isunmethylated in the C5 position, and the tag may be bound to an atom that would otherwise have been bound by the modification.

[0143] In some embodiments, the tag is not a fluorescent tag. In some embodiments, the label is not a fluorescent label. In some embodiments, neither the tag nor the label is fluorescent. Thus, in some embodiments, the label and / or tag does not consist of or comprise a fluorophore or fluorophore derivative that is capable of emitting light when excited, such as re-emitting light upon light excitation.

[0144] The method preferably does not comprise the use of bisulfite, such as bisulfite conversion of cytosine to uracil.

[0145] The method preferably does not comprise pyridine borane base conversion or enzymatic deamination of unmethylated cytosine.

[0146] The method preferably does not comprise the use of methyl-binding antibodies or methyl-DNA Immunoprecipitation (also referred to as “MeDIP-Seq”).

[0147] The method preferably does not comprise the use of methyl-binding domain protein (referred to as “MBD-Seq”).

[0148] The sequencing library may be suitable for use with high throughout sequencing methods. Sequencing the polynucleotides preferably comprises the use of next generation sequencing, such as sequencing applications on the Illumina platform. The method preferably does not comprise the use of a nanopore-based sequencing method.

[0149] The terms “epigenome” and “epigenetic” as used herein, unless otherwise specified, refer to the chemical modification of a polynucleotide or genome in such a way that gene expression is regulated.

[0150] In some embodiments, the polynucleotide sample may comprise or substantially consist of, and / or may have been fragmented to comprise or substantially consist of, polynucleotides having a length between 10 and 500 bp. In some embodiments, the polynucleotides may substantially or predominantly have a length of 50-475 nucleotides, such as 100-450 nucleotides, 125-425 nucleotides, or 150-400 nucleotides.

[0151] In some embodiments, the polynucleotide sample may comprise or substantially consist of, and / or may have been fragmented to comprise or substantially consist of, polynucleotides having a length corresponding to the DNA sequencing read length. In such embodiments, the polynucleotides may substantially or predominantly have a length of 100-250 nucleotides, preferably 150-180 nucleotides.

[0152] The method may further comprise a step of amplifying the polynucleotides. In some embodiments, the method may comprise the amplification of the polynucleotides after inactivation of the methyltransferase (i.e. after step 2 or step 3). In some embodiments, the method may comprise the amplification of the polynucleotides of the sequencing library after binding of the affinity label (i.e. after step 4). In some embodiments, the method may comprise the amplification of the polynucleotides of the first and / or second fraction (i.e. after step 5).

[0153] The terms “enriched”, “enriching”, and “enrichment” of polynucleotides as used herein, unless otherwise stated, refer to a polynucleotide concentration and / or proportion that is greater than the corresponding polynucleotide concentration and / or proportion in the initial (unenriched) sample. References to “enriching the labelled polynucleotide library” and similar terms refer to fractionating the sequencing library / polynucleotide sample into first and second fractions, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label. Likewise, references to “enriching the labelled sequencing library” or “enriching the labelled DNA library” and similar terms refer to fractionating the sequencing library / polynucleotide / DNA sample into first and second fractions, wherein the first fraction is enriched for polynucleotides / DNA molecules comprising an affinity label, and wherein the second fraction is enriched for polynucleotides / DNA molecules lacking an affinity label.

[0154] Applying a tag to unmodified nucleotide residues (step 1) is performed before inactivation of the methyltransferase (step 2) and before binding an affinity label to each tag (step 4).

[0155] In some embodiments, the method may further comprise, after inactivating the methyltransferase (step 2) and before binding an affinity label to each tag (step 4),segregating each polynucleotide strand. In such embodiments, segregating each polynucleotide strand may comprise performing:

[0156] (i) exactly two cycles of PCR; or

[0157] (ii) exactly one cycle of PCR.

[0158] In some embodiments, segregating each polynucleotide strand may comprise performing 10 or less cycles of DNA replication, 9 or less cycles of DNA replication, 8 or less cycles of DNA replication, 7 or less cycles of DNA replication, 6 or less cycles of DNA replication, 5 or less cycles of DNA replication, 4 or less cycles of DNA replication, 3 or less cycles of DNA replication. In some embodiments, segregating each polynucleotide strand may comprise performing 1 or 2 cycles of DNA replication.

[0159] In some embodiments, preparing the sample into a sequencing library may comprise the ligation of sequencing adapters to the polynucleotides in the sample. In such embodiments, the strand segregation step may be performed after the library preparation step (step 3). In such embodiments, the added sequencing adapters may provide primer binding sites that may be used for the segregation. For the avoidance of doubt, the step of segregating each polynucleotide strand would not be considered by the skilled person to represent “amplification” of the sample in the sense used in the art. For example, as shown in Figure 1C, only one, or at most two, cycles of PCR are required to ensure that each polynucleotide strand from the original sample is segregated into a separate new polynucleotides. The original polynucleotide strands cannot be further segregated by additional cycles of PCR, which will simply dilute the original strands within the sample. In embodiments that are described as comprising a step of amplifying the polynucleotides, amplification does not encompass strand segregation. Likewise, in embodiments that are described as comprising strand segregation of the polynucleotides, segregation does not encompass amplification.

[0160] The library preparation step (step 3) is performed before the fractionation step (step 5). In some embodiments, the steps of the method are performed in the numerical sequence in ascending order (i.e. in sequence from step 1 to step 6). In some embodiments, the library preparation step (step 3) may be performed before the affinity labelling and fractionation steps (i.e. before steps 4 and 5). In other embodiments, step 3 may be performed after step 4, and before step 5.

[0161] The steps comprising sequencing library preparation and affinity labelling (steps 1-4) are performed before fractionation of the sequencing library (step 5), and sequencingthe polynucleotides of the first and / or second fractions (step 6) is performed after fractionation (step 5).

[0162] In some embodiments, one or more aspect of the library preparation step, such as end repair, A-tailing, and / or adapter ligation, may be performed before step 1. In such embodiments, the remaining step(s) of library preparation maybe performed subsequently, such as after the inactivation of the methyltransferase (step 2), or after affinity labelling (step 4). In such embodiments, references to “preparing the polynucleotide sample into a sequencing library” or to “preparing the DNA sample into a sequencing library” refer to completion of the preparation of the sequencing library.

[0163] In some embodiments, the polynucleotide sample may be prepared into an affinity labelled sequencing library (steps 1-4) prior to fractionation.

[0164] In some embodiments, the method may be a “one pot” method, wherein all of the steps prior to fractionation (i.e. steps 1-4) are performed in a single container, thereby providing significant efficiencies in terms of time and reagents, and advantages in terms of automation. This approach has been found to maximise sensitivity, time, reagents and the overall yield of the polynucleotide enrichment.

[0165] In some embodiments, the method may comprise at most one sample purification step prior to fractionation (i.e. prior to step 5). Thus, the preparation of a labelled sequencing library (steps 1-4) may involve at most one sample purification step.

[0166] In some embodiments, binding an affinity label to each tag may comprise adding an affinity label precursor directly into the sequencing library preparation mixture, without a washing step.

[0167] As used herein, unless otherwise stated, the terms “label”, “labelled”, “labelling” and similar terms refer to the targeted binding (covalent or otherwise, either directly or indirectly) of a compound that facilitates selective enrichment of the targeted polynucleotides.

[0168] In some embodiments, the label may be suitable for use for enriching the labelled polynucleotides from a mixture comprising labelled and unlabelled polynucleotides.

[0169] In some embodiments, the label may be suitable for use directly for enriching the labelled polynucleotides. In other embodiments, a secondary compound that specifically binds the label, preferably with a high affinity, may be used for enrichment of the labelled polynucleotides.

[0170] In some embodiments, the affinity label may comprise biotin, and fractionating the sequencing library into first and second fractions may comprise fractionation using a capture agent comprising a biotin-binding protein.

[0171] As used herein, unless otherwise stated, the terms “method of’ and “method for”, such as “method of identifying” and “method for identifying” are intended to be interpreted interchangeably, to encompass methods “suitable for” the described purpose.

[0172] The inventors have found that the disclosed method provides significant advantages over previous methods of epigenetic analysis of cfDNA. The non-destructive nature of the disclosed method means that epigenetic analysis of the sample maybe performed in parallel with other analytical approaches, such as nucleotide sequencing.

[0173] In addition, the inventors have found that the disclosed method is highly efficient, allowing analysis of very low levels of input cfDNA sample. Moreover, the inventors have identified that previous “unmethylome” profiling approaches introduce bias in relation to densely modified polynucleotides, and the disclosed method avoids this detrimental bias. As discussed herein, these advantages have been made possible by minimising the loss of sample, by performing various operations in specific sequences and combinations.

[0174] The method may be a “one pot” method, wherein all of the steps, or all of the steps prior to fractionation (i.e. steps 1-4), are performed in a single container, thereby providing significant efficiencies in terms of time and reagents, and advantages in terms of automation. This approach has been found to maximise sensitivity, time, reagents and the overall yield of the polynucleotide enrichment.

[0175] The “nucleotide modification status” and “modification status of nucleotide residues” as used herein, unless otherwise stated, refer to the presence (modified) or absence (unmodified) of any chemical modification in a target position on a nucleotide residue that may be catalysed by a methyltransferase enzyme. Thus, the disclosed method maycomprise determining the modification status of any position within a nucleotide that may be chemically modified by a methyltransferase enzyme. Such methyltransferase catalysed modifications include, for example, the modification of cytosine (at the C5 or N4 position), adenine (at the N6 position).

[0176] The nucleotide residues may be cytosine residues and / or adenine residues.

[0177] Accordingly, the method comprise determining the modification status at target positions of cytosine and / or adenine residues in a polynucleotide.

[0178] In some embodiments, the methyltransferase enzyme may be configured to modify the cytosine of a CpG dinucleotide that is unmodified in the C5 position. In such embodiments, the modification status may comprise the modification status at the cytosine C5 position of CpG dinucleotides in the target marker region.

[0179] The method may comprise obtaining the modification status at the cytosine C5 position of each CpG dinucleotide in the target marker region. In such embodiments, step (1) of the method may comprise:

[0180] 1. using a methyltransferase enzyme configured to modify the cytosine C5 position of a CpG dinucleotide motif to apply a tag to each unmodified cytosine residue of the cfDNA sample, wherein each unmodified cytosine residue is the cytosine of a CpG dinucleotide motif that is unmodified in the C5 position.

[0181] In some embodiments, the method comprises sequencing the DNA of the first fraction only. In some embodiments, the method may further comprise sequencing the DNA of the first fraction, and using the sequencing information to determine the modification status at the cytosine C5 position of each CpG dinucleotide in the DNA sample.

[0182] The method may further comprise a step of amplifying the DNA. In some embodiments, the method may comprise the amplification of the DNA after inactivation of the methyltransferase (i.e. after step 2 or step 3). In some embodiments, the method may comprise the amplification of the sequencing library, after binding of the affinity label (i.e. after step 4). In some embodiments, the method may comprise the amplification of the DNA of the first and / or second fraction (i.e. after step 5).

[0183] The “modification status of cytosine residues” as used herein, unless otherwise stated, refers to the presence (modified) or absence (unmodified) of any methyltransferase catalysed chemical modification of cytosine.

[0184] In particular, the modification may comprise modification at the C5 position of cytosine. A cytosine residue maybe understood to have the following structure:

[0185]

[0186] In an unmodified cytosine residue R1maybe understood to be H. R1may also be referred to herein as the “C5 position”.

[0187] In a modified cytosine residue R1maybe anything other than H. Thus, “modified cytosine” refers to any cytosine residue that has been modified in any way at the C5 position, including, in particular, 5-methylcytosine (5-mC) and its oxidized products 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). It may be therefore appreciated that in modified cytosine, R1may be methyl, CH2OH, COH or COOH.

[0188] Alternatively, the modification may comprise modification at the N4 position of cytosine. Accordingly, a modified cytosine may have the following structure:

[0189]

[0190] where R1maybe anything other than H. Thus, “modified cytosine” refers to any cytosine residue that has been modified in any way at the N4 position. It may be therefore appreciated that in modified cytosine, R1may be methyl, CH2OH, COH or COOH.

[0191] The method may comprise obtaining the modification status at the N4 position of cytosine residues in the target marker region.

[0192] In some embodiments, the methyltransferase enzyme may be configured to modify unmodified cytosine residues in the N4 position. In such embodiments, the modification status may comprise the modification status at the cytosine N4 position in the target marker region. In such embodiments, step (1) of the method may comprise: 1. using a methyltransferase enzyme configured to modify a cytosine residue in the

[0193] N4 position to apply a tag to each unmodified cytosine residue of the sample, wherein each unmodified cytosine residue is unmodified in the N4 position.

[0194] In some embodiments, the method comprises sequencing the DNA of the first fraction only. In some embodiments, the method may further comprise sequencing the DNA of the first fraction, and using the sequencing information to determine the modification status at the N4 position of each cytosine residue in the DNA sample.

[0195] The “modification status of adenine residues” as used herein, unless otherwise stated, refers to the presence (modified) or absence (unmodified) of any chemical modification at the N6 position of adenine. An adenine residue may be understood to have the following structure:

[0196]

[0197] In an unmodified adenine residue R1maybe understood to be H.

[0198] In a modified adenine residue R1maybe anything other than H. Thus, “modified adenine” refers to any adenine residue that has been modified in anyway at the N6 position, including, in particular,6-methyladenine (m6A). It maybe therefore appreciated that in modified adenine, R1maybe methyl, CH2OH, COH or COOH.

[0199] The method may comprise obtaining the modification status at the N6 position of adenine residues in the target marker region.

[0200] In some embodiments, the methyltransferase enzyme may be configured to modify unmodified adenine residues in the N6 position. In such embodiments, the modification status may comprise the modification status at the adenine N6 position in the target marker region. In such embodiments, step (1) of the method may comprise:1. using a methyltransferase enzyme configured to modify an adenine residue in the N6 position to apply a tag to each unmodified adenine residue of the sample, wherein each unmodified adenine residue is unmodified in the N6 position.

[0201] In some embodiments, the method comprises sequencing the DNA of the first fraction only. In some embodiments, the method may further comprise sequencing the DNA of the first fraction, and using the sequencing information to determine the modification status at the N6 position of each adenine residue in the DNA sample.

[0202] As used herein, “unmodified” and “unmethylated” refer to all nucleotides that are unmodified in any way (such as methylated, hydroxymethylated, carboxylated, acylated).

[0203] The method comprises the detection of unmodified nucleotide residues in a polynucleotide.

[0204] In embodiments in which the method comprises determining, for a plurality of nucleotides, the presence (modified) or absence (unmodified) of any chemical modification catalysed by a methyltransferase, “modification status” may also be referred to as the “profile”. Thus, the disclosed method may be used to determine a profile of methyltransferase catalysed modifications within a polynucleotide sample.

[0205] The method may comprise the detection of unmodified cytosine residues in CpG dinucleotides of a DNA sample. The terms “CpG”, “CpG site”, and “CpG dinucleotide”, are used interchangeably herein to refer to a cytosine-phosphate-guanine sequence in a 5’ to 3’ direction in the backbone of a nucleic acid.

[0206] The terms “CpG modification status” and “modification status” as used interchangeably herein, unless otherwise stated, refer to the presence (modified) or absence (unmodified) of any chemical modification at the C5 position of cytosine within one or a plurality of CpG dinucleotides.

[0207] In embodiments in which the method comprises determining, for a plurality of CpG dinucleotides, the presence (modified) or absence (unmodified) of any chemical modification at the C5 position of each of the plurality of cytosines, the “CpG modification status” and “modification status” may also be referred to as the “profile”.

[0208] The terms “epigenome” and “epigenetic” as used herein, unless otherwise specified, refer to the chemical modification of a polynucleotide or genome in such a way that gene expression is regulated.

[0209] The method may be an in vitro method performed on a polynucleotide sample that has previously been obtained from a subject.

[0210] The term “subject”, as used herein, may refer to any type of organism, including for example, a mammalian species (such as a human or domesticated animal), other animal species, a plant such as a crop, or other type of organism, including single celled organisms, and viruses. The subject maybe a developing organism, such as an embryo or foetus. The subject may be a healthy individual. The subject may be an individual that has, or is suspected of having, a disease or predisposition to a disease. The subject may be an individual in need of therapy or suspected of needing therapy.

[0211] The method may be an in vitro method of diagnosing disease in a subject, the method further comprising diagnosing the disease based on the identification in the sample of DNA from the specific tissue or cell type.

[0212] The method may be a method for determining the disease status of a subject.

[0213] Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject using the disclosed method, and determining the disease status based on the identification of DNA from the specific tissue or cell type.

[0214] The method may be a method for diagnosing a disease in a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject using the disclosed method, and diagnosing the disease based on the identification of DNA from the specific tissue or cell type.

[0215] The method maybe a method for making a disease prognosis in a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject using the disclosed method, and making a disease prognosis based on the identification of DNA from the specific tissue or cell type.

[0216] The level of DNA from the specific tissue or cell type may be determined relative to a reference sample or plurality of reference samples. For example, the reference sample or samples may comprise DNA derived from a known tissue and / or cell type. The reference sample may comprise cfDNA from a healthy subject or a population of healthy subjects. The reference sample may comprise cfDNA from a diseased subject or population of diseased subjects. The reference sample may comprise cfDNA from a subject or a population of subjects to which an active agent has been administered. The reference sample may comprise cfDNA from the same subject as the test sample, taken at a different time point. For example, the reference sample may comprise cfDNA from a subject prior to the administration of an active agent.

[0217] The method may be a method for treating a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject using the disclosed method, diagnosing a disease based on the identification of DNA from the specific tissue or cell type, and providing a therapeutic composition to the subject to treat the disease based on the diagnosis.

[0218] The method may be a method for determining a personalised or precision method of treatment for a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject using the disclosed method, determining the disease status of the subject based on the identification of DNA from the specific tissue or cell type, and determining a personalised medical treatment for the subject based on the disease status.

[0219] The method may be a personalised or precision method of treating a subject.

[0220] Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject using the disclosed method, determining the disease status of the subject based on the identification of DNA from the specific tissue or cell type, and providing a personalised medical treatment to the subject based on the disease status.

[0221] The subject maybe an individual that has been diagnosed with having a disease. The subject may be an individual that has been identified as being predisposed to, or at risk of having, a disease. The subject may be an individual that has not been diagnosed with having a disease.

[0222] The subject maybe an individual that has been diagnosed with cancer. The subject may be pending or undergoing treatment such as a cancer therapy. The subject can be in remission of a cancer.

[0223] Cancer can be identified on the basis of epigenetic variations. Cancer may be associated with both DNA hypomethylation and hypermethylation, but these two types of epigenetic abnormalities may affect different DNA sequences, and occur at different stages of cancer progression. For example, genomic hypermethylation in cancer maybe seen in CpG islands in gene regions, whereas hypomethylation maybe observed in repeated DNA sequences in cancer, including heterochromatic DNA repeats, retrotransposons, and endogenous retroviral elements. In addition, unique sequences, such as transcription control sequences, are often subject to cancer-associated hypomethylation. These epigenetic changes may be detected using the disclosed method, and may be used to identify DNA in the sample from a specific cancer cell type.

[0224] Thus, the method maybe a method of diagnosing cancer in subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type, which may be a specific cancer cell type, in a cfDNA sample from the subject using the disclosed method, and making a cancer diagnosis based on the identification of DNA from the specific tissue or cell type, or specific cancer cell type.

[0225] The frequency of cancer-linked DNA hypomethylation, the nature of the affected sequences, and the absence of associations with DNA hypermethylation are belived to suggest a role for DNA hypomethylation early in carcinogenesis and cancer formation, but can also be associated with tumor progression.

[0226] Thus, the method maybe a method of detecting cancer in a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type, which may be a specific cancer cell type in a cfDNA sample from the subject using the disclosed method, and determining the presence or absence of cancer based on the identification of DNA from the specific tissue or cell type, or specific cancer cell type.

[0227] The method may be a method of detecting any type of cancer. Different types of cancer maybe preferentially detected and / or analysed using different sampling approaches based on the disclosed method.

[0228] The method may be a method of treating cancer in a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type, which maybe a specific cancer cell type in a cfDNA sample from the subject using the disclosed method, diagnosing a cancer based on the identification of DNA from the specific tissue or cell type, or specific cancer cell type, and providing a therapeutic composition to the subject to treat the cancer based on the diagnosis.

[0229] The method may be a method of determining a personalised or precision method of cancer treatment for a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type, which may be a specific cancer cell type in a cfDNA sample from the subject using the disclosed method, determining the genetic profile of the cancer based on the nucleotide modification status of the DNA, and determining a personalised medical treatment for the subject based on the genetic profile of the cancer.

[0230] The method may be a personalised or precision method of treating cancer in a subject.

[0231] Accordingly, the method may comprise identifying DNA from a specific tissue or cell type, which maybe a specific cancer cell type in a cfDNA sample from the subject using the disclosed method, determining the genetic profile of the cancer based on the nucleotide modification status of the DNA, and providing a personalised medical treatment to the subject based on the genetic profile of the cancer.

[0232] The method may be an in vitro method performed on a DNA sample that has previously been obtained from a tissue biopsy. Biopsy is a diagnostic procedure for cancers and other diseases. For example, tissue biopsy may provide material for cancer genotyping, which may assist in the design of targeted therapeutic approaches.

[0233] Liquid biopsy, which has the advantage of minimal invasiveness, has shown potential in detecting cancers, including early stage cancers and pre-cancerous lesions. The analysis of cell-free DNA (“cfDNA” or “circulating cfDNA”), which refers to DNA present at very low concentration in various bodily fluids, comprises extracellular nucleic acid fragments, for example, released by damaged cells during apoptosis, necrosis, or secretion. cfDNA has been found to exhibit the genetic and epigenetic alterations of cancers, including mutations, copy number alterations, chromosomal rearrangements, hypermethylation, and hypomethylation. The analysis of cfDNA has the potential to revolutionise the detection of early stage cancers and other diseases. In samples fromcancer patients, cfDNA may comprise circulating tumor DNA (“ctDNA”), which is cell free tumor-derived fragmented DNA in a bodily fluid. Thus, cfDNA may comprise ctDNA. As demonstrated in the enclosed examples, the disclosed method has advantageously been found to be capable of providing high quality and consistently reproducible results from the very low concentrations of nucleic acid that are typically present in liquid biopsy (such as circulating cfDNA) samples. Thus, the sample for use in the disclosed method may be a cfDNA sample. The sample may consist of or comprise ctDNA.

[0234] Various liquid biopsy samples may be used for the analysis of cfDNA, including blood, plasma, urine, and spinal fluid. Preferably the liquid biopsy sample may be a blood or plasma sample.

[0235] Thus, the method may be an in vitro method of diagnosing disease in a cfDNA sample from a subject. Accordingly, the method may comprise identifying DNA from a specific tissue or cell type in a cfDNA sample from the subject, and diagnosing the disease based on the identification of DNA from the specific tissue or cell type.

[0236] The method may be a method of diagnosing the recurrence of cancer in a subject from which a tumour has previously been removed. Accordingly, the method may comprise identifying DNA from the specific tumour in a cfDNA sample from the subject using the disclosed method, and diagnosing the recurrence of the cancer in the subject based on the identification of the DNA in the cfDNA sample. The cfDNA sample from the subject maybe a blood sample.

[0237] Sample

[0238] The cfDNA sample for use in the disclosed method may be obtained from any type of cell or tissue. For example, the sample maybe obtained from tissue, blood, plasma, serum, urine, saliva, stool, cerebrospinal fluid, buccal swab, pleural tap, etc.. The sample may be obtained from tissue. The sample may be obtained from blood. The

[0239] DNA sample may comprise ctDNA. For example, the DNA sample maybe a cfDNA sample from peripheral blood. A “cell-free” sample as used herein, refers to nucleic acids not contained within or otherwise bound to a cell or, remaining in a sample following the removal of intact cells. Cell-free nucleic acids can include, for example, all non-encapsulated nucleic acids sourced from a bodily fluid (e.g., blood, plasma, serum, cerebrospinal fluid, etc.) from a subject. The cfDNA maybe released into bodily fluidthrough a cell death process. The cfDNA may comprise DNA released into bodily fluid from cancer cells, and may be referred to as comprising circulating tumor DNA (ctDNA).

[0240] Methods of preparing cfDNA samples will be known to the skilled person. Any method that is suitable for preparing a cfDNA sample for analysis, such as sequencing, may be used.

[0241] The sample may comprise fragmented DNA. Fragmentation maybe performed using any method used in the analysis of DNA, such as any fragmentation method used in the preparation of a DNA sample for genetic sequencing. For example, the DNA may be fragmented enzymatically, chemically by acoustic shearing, mechanical shearing (example, French pressure cells), sonicating, hydrodynamic shearing or chemically (for example, heat and divalent metal cation).

[0242] In some implementations of the disclosed method, fragmentation of the DNA sample is not required. In such embodiments, the method does not include fragmentation of the DNA sample. For example, in embodiments in which the DNA sample is degraded or fragmented, such as when cfDNA is extracted from blood, the DNA sample may be used directly in the disclosed method. Typically, cfDNA extracted from blood substantially comprises DNA fragment sizes of 50-300 base pairs (bp) in length.

[0243] The method may comprise the selection of DNA fragments of a desired length.

[0244] Thus, in some embodiments, the method may comprise, before the use of a methyltransferase (step 1), a step of fragmenting the DNA and / or selecting DNA fragments of a desired length.

[0245] The method may comprise the use of polynucleotides, such as DNA fragments, substantially or predominantly having a length between 10 and 500 bp, such as between 30 and 400 bp, and preferably between 50 and 300 bp in length. In some embodiments, the method may comprise the use of polynucleotides, such as DNA fragments, substantially or predominantly having a length in the region of between 100 and 250 bp, preferably between about 150 and 180 bp, to match the sample to the DNA sequencing read length.

[0246] The method may comprise the use of polynucleotides corresponding to an amount of DNA in the range of about 1 fg to about 1 µg, such as about 10 fg to about 100 ng, about 100 fg to about 10 ng, about 1 pg to about 1 ng. The sample may comprise a quantity of DNA in the picogram range. The sample may comprise less than 1µg of DNA, such as less than 500ng, less than 100ng, or less than 10ng of DNA. Preferably, the sample comprises between 1ng and 100ng of DNA.

[0247] Derivatisation of DNA - Tag

[0248] The DNA may be derivatised using a methyltransferase enzyme to apply a tag to unmodified nucleotide residues. For example, the DNA may be derivatised using an appropriate methyltransferase enzyme to apply a tag to specific nucleotide residues that are unmodified in target positions. Thus, to determine the modification status of a specific nucleotide residue at a specific target position, a methyltransferase enzyme may be used that is configured to apply a tag to the target nucleotide residue in the target position.

[0249] In some embodiments, the same tag may be used to derivatise different unmodified nucleotides and / or different target positions.

[0250] In other embodiments, different tags may be used to derivatise different unmodified nucleotides and / or different target positions.

[0251] In some embodiments, the DNA may be derivatised with different tags (e.g. on different unmodified nucleotides) sequentially, for example, with the inactivation of the first methyltransferase before the addition of a second, different methyltransferase.

[0252] The use of a plurality of different tags advantageously allows the tags to be independently functionalised, for example, to provide selective

[0253] enrichment / fractionation.

[0254] As used herein, unless otherwise indicated, references to the “target position” in which an unmodified nucleotide residue is unmodified refer to a specific position within the chemical structure of the nucleotide.

[0255] The tag maybe applied in the cytosine C5 position. Accordingly, the fragmented DNA sample will comprise tagged residues. A tagged cytosine residue may be understood to have the following structure:

[0256]

[0257] wherein R2is the tag.

[0258] The tag maybe applied in the N4 position in cytosine. Accordingly, the fragmented DNA sample will comprise tagged residues. A tagged cytosine residue may be understood to have the following structure:

[0259]

[0260] wherein R2is the tag.

[0261] Similarly, a tag maybe added at the N6 position of adenine, the N2 or N7 position of guanine or at the 2’-0H position of ribose. In some embodiments, a tag at the 2’-0H position of ribose is a tag at the 2’-0H position of a terminal ribose.

[0262] Accordingly, a tagged adenine residue may be understood to have the following structure:

[0263]

[0264] wherein R2is the tag.

[0265] The term “tag”, which may also be referred to as a “linker”, a “functional linker” or “DNA tag”, as used herein, unless otherwise specified, refers to a reactive moiety that is applied site-specifically to the DNA, such as fragmented DNA. DNA that has been tagged in this way may be referred to as “derivatised”.

[0266] The disclosed method may comprise the use of a methyltransferase cofactor analogue, such as a synthetic methyltransferase cofactor analogue, comprising the tag and a methyltransferase-binding moiety. Thus, using a methyltransferase enzyme to apply a tag to each unmodified nucleotide residue may comprise the use of a methyltransferase cofactor analogue. Thus, the method may comprise the use of a methyltransferase enzyme to catalyse the transfer of the tag from the methyltransferase cofactor analog to an unmodified nucleotide residue, such as to the C5 position of a cytosine base of an unmodified CpG dinucleotide, in a DNA sample. The presence of a modification, such as a methyl group or other chemical modification of the nucleotide residue, such as in the C5 position within a CpG dinucleotide, prevents the transfer of the tag. Thus, in the disclosed method, only nucleotides, such as CpG dinucleotides, that are unmodified (such as unmethylated) in this position may be labelled with a tag.

[0267] The methyltransferase cofactor may be an ion of formula (I):

[0268]

[0269] wherein, X is S or Se;

[0270] L1is -CH2- or -CH2CH2-;

[0271] R2is the tag;

[0272] R3and R4are independently H or an optionally substituted C1-6alkyl an optionally substituted C2-6alkenyl or an optionally substituted C2-6alkynyl; or R3and R4together with the nitrogen to which they are attached, form an optionally substituted 5- or 6-membered heterocyclyl ring; and

[0273] R5is NH2, NHBoc or H;

[0274] or a salt, solvate or tautomer thereof.

[0275] The ion of formula (I) may be provided together with a counterion. The counterion may be an organic or inorganic anion carrying one or more negative charges. The counterion may be formate or acetate.

[0276] R2maybe -CH2-U-[L3]m-[HM]n-[L2]p-[R6]q, wherein:

[0277] m, n, p and q are each independently selected from 0 and 1;

[0278] L2is a linker;

[0279] HM is a hydrolysable moiety;

[0280] L3 is a linker;

[0281] U is an unsaturated group selected from an alkene, an alkyne, an aromatic group (e.g. aryl), a carbonyl group, SO and S02;

[0282] R6is a heavy atom or a heavy atom cluster suitable for phasing of X-ray diffraction data, a radioactive or stable rare isotope, a fluorophore, a fluorescence quencher, an affinity tag, a crosslinking agent, a nucleic acid cleaving reagent, a spin label, a chromophore, a protein, peptide or amino acid which may optionally be modified a nucleotide, nucleoside or nucleic acid which may optionally be modified, a carbohydrate, a lipid, a transfection reagent, an intercalating agent, a nanoparticle or bead, or a functional group,

[0283] wherein the functional group is selected from the group consisting of: an amino group (including a protected amino), a thiol group, a 1,2-diol group, a hydrazino group, a hydroxyamino group, a haloacetamide group, a maleimide group, a cyanide group, a cyclic hydrocarbon (such as a bridged cyclic hydrocarbon (e.g. norbornene) or a cycloalkyl group (e.g. a C3-6 cycloalkyl), a halo group (e.g. -F, -Cl, -Br, -I), an aldehyde group, a ketone group, a 1,2-aminothiol group, a azido group, an isothiocyanate or thiocyanate group, an alkene group, such as a terminal alkene, an alkyne group, such as a terminal alkyne group, a 1,3-diene function, a dienophilic function (e.g. an activated carbon-carbon double bond), an arylhalide group, an arylboronic acid group, a terminal haloalkyne group, a terminal silylalkyne group, -N=C=O; -N=C=S, -0-C(0)NH2, a protected amino, a group comprising a sterically strained alkyne or alkene (such as norbornene or DBCO), a nitrone, a tetrazine, a tetrazole, and 1,2-aminothiol group.

[0284] In embodiments where R4is an optionally substituted C1-4alkyl an optionally substituted C2-4alkenyl or an optionally substituted C2-4alkynyl, the alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more substituents selected from the group consisting of: -NR7R8; -OH; -SH; -CN; -C(O)OR7; -C(O)R7;

[0285] C(O)NR7R8; N3; and halo, wherein R7and R8are independently H or a C1-4alkyl. Halo may be F, Cl, Br or I.

[0286] Similarly, in embodiments where R3and R4together with the nitrogen to which they are attached, form an optionally substituted 5- or 6-membered heterocyclyl ring, the 5-or 6-membered heterocyclyl ring may be unsubstituted, or substituted with one or more substituents selected from the group consisting of: -NR7R8; -OH; -SH; -CN; -C(O)OR7; -C(O)R7; C(O)NR7R8; N3; and halo, wherein R7and R8are independently H or a C1-4 alkyl. Halo may be F, Cl, Br or I.

[0287] Synthetic methyltransferase cofactors are described in more detail in PCT / GB2022 / 052438, EP3186266B1 and US8008007B2. It maybe appreciated that preferred embodiments of the X, L1, R2, R3and R4groups in the compound of formula

[0288] (I) may be as defined for the equivalent groups in these applications.

[0289] X may be S.

[0290] L1may be -CH2CH2-.

[0291] R3maybe H. Alternatively, R3maybe an optionally substituted C1-4alkyl an optionally substituted C2-4alkenyl or an optionally substituted C2-4alkynyl, more preferably an optionally substituted methyl or an optionally substituted ethyl. The alkyl, alkenyl or alkynyl may be unsubstituted or substituted with an OH. Accordingly, R3may be -CH2CH20H.

[0292] R4maybe H.

[0293] R5may be NH2.

[0294] In some embodiments, q is 1. In some embodiments, R6is -N3.

[0295] p may be 1.

[0296] L2may be a linker comprising a backbone of between 1 and 50 atoms, between 2 and 40 atoms, between 3 and 30 atoms, between 4 and 20 or between 5 and 15 atoms. The backbone may be made up of carbon, oxygen and / or nitrogen atoms. In embodiments where the linker comprises a cyclic group, the backbone may be understood to consist of the atoms which define the shortest possible route between the two ends of the linker group.

[0297] In some embodiments, L2comprises between 1 and 5 groups selected from an optionally substituted hydrocarbon, an optionally substituted polyether chain, an arylene moiety and a (C=O)NH group.

[0298] The hydrocarbon may be an optionally substituted alkylene, preferably an optionally substituted C1-10alkylene and more preferably a C1-5alkylene. The optionally substituted polyether chain may be an optionally substituted polyethylene glycol chain. The polyethylene glycol chain may comprise up to 15 monomers, up to 10 monomers or up to 5 monomers of ethylene glycol. In some embodiments, the polyethylene glycol chain consists of between 1 and 5 or between 2 and 3 monomers of ethylene glycol. The arylene moiety maybe a C6H4phenylene ring.

[0299] Accordingly, in some embodiments, L2maybe:

[0300]

[0301] wherein w is an integer from between 1 and 15, e.g. between 2 and 10 or between 3 and 5. In some embodiments, w is 2 or 3.

[0302] Alternatively, in some embodiments, p is o.

[0303] In some embodiments, n is 1.

[0304]

[0305]

[0306] , wherein Rxis hydrogen, deuterium or a Ci-4alkyl. The Ci-4alkyl maybe methyl.

[0307] The hydrolysable moiety may be a Schiff base, for example, an imine moiety, an oxime moiety and / or a hydrazone moiety.

[0308] In some embodiments, the hydrolysable moiety comprises a disulphide (S-S) bond.

[0309] In some embodiments, the hydrolysable moiety is

[0310]

[0311] In some embodiments, n is o.

[0312] In some embodiments, m is 1. L3may be a linker comprising a linear chain of from 1 to 20, from 2 to 15, from 3 to 10 or from 4 to 9 atoms. The atoms may be carbon, oxygen and / or nitrogen atoms). The linker may be substituted or unsubstituted. In some embodiments, L3comprises an optionally substituted hydrocarbon (e.g. an alkyl) chain. In some embodiments, L3comprises an optionally substituted linear C1-10alkyl chain, e.g. an optionally substituted C2-8or an optionally substituted C4-6alkyl chain. In some embodiments the alkyl chain is unsubstituted. In some embodiments the alkyl chain is substituted. In some embodiments, L3is a linear, unsubstituted C2, C3or C4alkyl chain.

[0313] In some embodiments,

[0314]

[0315] Accordingly, in some embodiments, R2is

[0316]

[0317] . In alternative

[0318] embodiments,

[0319]

[0320] In some embodiments, the synthetic methyltransferase cofactor maybe:

[0321]

[0322] , where R is H.

[0323] The above compound may be called ETA-AdoHcy-N3

[0324] Derivatisation of DNA - Methyltransferase

[0325] The methyltransferase may be any methyltransferase that is capable of using S-adenosyl methionine as a cofactor. Thus, the methyltransferase maybe an S-adenosylmethionine-dependent methyltransferase, such as an S-adenosyl-L-methionine-dependent methyltransferase.

[0326] The methyltransferase may be a cytosine-5 (C5) methyltransferase, such as a bacterial cytosine C5 methyltransferase.

[0327] The methyltransferase may be an adenine methyltransferase, such as a bacterial adenine methyltransferase. For example, the methyltransferase maybe M. TaqI, which is a DNA adenine methyltransferase.

[0328] The methyltransferase may be a methyltransferase from Mycoplasma.

[0329] The methyltransferase maybe a constitutively active methyltransferase.

[0330] The methyltransferase maybe one of the enzymes described in US 2017 / 0283453.

[0331] The methyltransferase may be M.MpeI, M. Hhal, M. SssI, M. AccII, M. MspI or M. TaqI. The methyltransferase maybe an active mutant, variant, and / or fragment of M.MpeI, M. Hhal, M. SssI, M. AccII, M. MspI or M. TaqI.

[0332] M.MpeI has been found to be particularly advantageous for use in the disclosed method, in part due to being particularly non-selective in terms of target locus. Thus, the methyltransferase maybe M.MpeI or an active mutant, variant, and / or fragment thereof.

[0333] Although methyltransferase enzymes share a relatively low level of sequence similarity, they do share a highly conserved structural fold. This conserved fold is known as the Rossmann fold and comprises a series of beta strand and alpha helical segments, in which the beta strands are hydrogen bonded to form a beta-sheet.

[0334] The cofactor binding pocket of the methyltransferase enzyme may be modified within the Rossman fold, for example, by substitution of one or more amino acids, to improve the suitability of the enzyme for use in the disclosed method, such as, for example, by improving cofactor compatibility. For example, one or more amino acids within the Rossman fold of the methyltransferase enzyme may be substituted, for example, to reduce or relieve potential steric interaction with the cofactor analogue.

[0335] The methyltransferase may be modified such that an amino acid having a relatively large side chain, such as, for example, glutamine or asparagine may be substituted for an amino acid comprising a shorter side chain, such as, for example, alanine. The use of a methyltransferase enzyme that has been modified in this way may be particularly desirable when larger cofactor analogues are used, such as cofactor analogues comprising transferrable groups with longer alkyl-chains than those with shorter chains.

[0336] The methyltransferase may be any bacterial cytosine C5 methyltransferase enzyme comprising one or more, such as 2, 3, 4, 5, 6, or 7, amino acid substitutions in the Rossman fold.

[0337] The methyltransferase may be any bacterial cytosine C5 methyltransferase enzyme comprising an amino acid substitution in the position of the amino acid residue of the Rossman fold corresponding to the residue that is Gln82, Tyr254, and / or Asn304 in the wild type sequence of the M. HhaI methyltransferase (i.e. the sequence having the NCBI accession number P05102).

[0338] The methyltransferase may be any bacterial cytosine C5 methyltransferase enzyme comprising an alanine residue in the position of the amino acid residue of the Rossman fold corresponding to the residue that is Gln82, Tyr254, and / or Asn304 in the wild type sequence of the M. HhaI methyltransferase (i.e. the sequence having the NCBI accession number P05102).

[0339] The methyltransferase maybe an M.MpeI methyltransferase. The M.MpeI methyltransferase enzyme has been found to be particularly advantageous for use in the disclosed method due to non-selectively targeting any and all CpG dinucleotides for modification.

[0340] The methyltransferase may be, or may comprise, a variant, and / or fragment of the wild type M.MpeI sequence, which is defined as the sequence having the NCBI accession number BAC44284.

[0341] The methyltransferase may be, or may comprise, a variant, and / or fragment of the wild type M.MpeI sequence, comprising at least 80% sequence identity, such as at least 85%, 90%, or 95% sequence identity to the wild type M.MpeI sequence.

[0342] The methyltransferase may comprise one or more, such as 2, 3, 4, 5, 6 or 7 amino acid substitutions relative to the wild type M.MpeI sequence having the NCBI accession number BAC44284.

[0343] The use of the methyltransferase enzyme to apply the tag to unmodified nucleotides, such as unmodified CpG dinucleotides, may be carried out under conditions which enable the methyltransferase to transfer the tag from the methyltransferase cofactor analogue to the target DNA.

[0344] The reaction mixture may be incubated at a temperature of from 10 to 6o°C, from 20 to 5O°C, or from 30 to 4O°C. Preferably, the reaction mixture may be incubated at a temperature of about 37°C.

[0345] The incubation may be performed for a time sufficient to enable transfer of the tag to all of the available unmodified nucleotides, such as unmodified CpG dinucleotides, in the fragmented DNA sample. The incubation may be performed for a period of 5 minutes to

[0346] 5 hours, 10 minutes to 4 hours, 15 minutes to 3 hours, 30 minutes to 2 hours, or 40 to 90 minutes. Preferably the incubation is performed for a period of about 1 hour.

[0347] The incubation may be performed in a suitable buffer at a pH that is selected based on the methyltransferase that is being used. For example, the pH may be between 7.5 and

[0348] 8.5, such as between 7.8 and 8.2, or about pH 8.

[0349] Methii [transferase inactivation

[0350] After an appropriate incubation to label the unmodified nucleotides, such as unmodified CpG dinucleotides, in the sample with a tag, the presence of methyltransferase in the subsequent processing of the sample has been found to reduce the efficiency of the method. Thus, the method comprises the inactivation of the methyltransferase enzyme.

[0351] In some embodiments, methyltransferase enzymes have been found to bind tightly to DNA, thereby inhibiting downstream processing of the DNA. Methods comprising removal of the methyltransferase or purification of the sample have been found to reduce the efficiency of the process due to the additional time and reagents required and due to the loss of sample.

[0352] In some embodiments, the methyltransferase enzyme may be inactivated in the reaction mixture. The inactivation of the methyltransferase in this way has surprisingly been found to provide significant processing efficiencies in the disclosed method. The terms “inactivated” and “inactivation” as used herein, unless otherwise specified, refer to any alteration in the structure and / or function of the methyltransferase that prevents further activity of the methyltransferase on the target DNA. Thus, the terms “inactive” and “inactivated” as used herein, unless otherwise specified, refer to an enzyme that has less than 10%, such as less than 5%, less than 2%, or preferably less than 1% of its maximum activity.

[0353] Alterations in the structure and / or function of the methyltransferase that prevent further activity of the methyltransferase on the target DNA may include, for example, denaturation, modification, inhibition, and / or fragmentation of the methyltransferase. Thus, in some embodiments, inactivation of the methyltransferase may comprise denaturation of the methyltransferase. In some embodiments, inactivation of the methyltransferase may comprise modification of the methyltransferase. In some embodiments, inactivation of the methyltransferase may comprise inhibition of the methyltransferase. In some embodiments, inactivation of the methyltransferase may comprise fragmentation of the methyltransferase.

[0354] The methyltransferase may be inactivated by any suitable method. Suitable methods include changing the environmental conditions of the methyltransferase, and targeted inactivation of the methyltransferase.

[0355] Changing the environmental conditions may consist of or comprise, for example, changing the temperature and / or pH of the reaction mixture.

[0356] Thus, in some embodiments, inactivation of the methyltransferase may comprise incubation of the reaction mixture at a temperature of from 55 to 85°C, from 60 to 8o°C, or from 65 to 75°C. In some embodiments, inactivation of the methyltransferase may comprise incubation of the reaction mixture at a temperature of from 55 to 65°C, such as at or about 6o°C, or from 75 to 85°C, such as at or about 8o°C.

[0357] Inactivation of the methyltransferase may comprise incubation at an elevated temperature for a period of 5 minutes to 1 hour, or 10-30 minutes. Preferably inactivation of the methyltransferase may comprise incubation at an elevated temperature for about 15 minutes.

[0358] Targeted inactivation of the methyltransferase may comprise the addition of an agent to alter the structure and / or function of the methyltransferase. Such an agent may comprise, for example, a methyltransferase inhibitor. Any suitable methyltransferase inhibitor may be used, including, for example, 5-azacitidine, decitabine, clofarabine, arsenic trioxide, guadecitabine, RX-3117, 5-fluoro-2’-deoxycytidine, 5,6-dihydro-5-azacytidine, cladribine, fludarabine, fazarabine, procaine, EGCG, hydralazine, genistein, equol, curcumin, disulfiram, resveratrol, and / or caffeic acid. The methyltransferase inhibitor maybe a S-Adenyl-l-methionine (SAM) analogue, such as sinefungin or S-adenosyl-l-homocysteine (SAH).

[0359] The methyltransferase may be inactivated in the reaction mixture after an appropriate incubation to label the unmodified nucleotides, such as unmodified CpG dinucleotides, with a tag, thereby terminating the derivatisation reaction. Advantageously, the presence of the inactivated methyltransferase has not been found to be detrimental to subsequent processing. On the contrary, the inactivation of the methyltransferase enzyme in the reaction mixture this way, rather than by removal or dilution, has been found to provide increased efficiencies and significantly improved yields in subsequent steps of the process.

[0360] The inactivation of the methyltransferase may, therefore, provide significant advantages by removing the requirement for purification of the DNA at this stage, and permitting the efficient combination of the methyltransferase and library preparation processes in a single reaction mixture.

[0361] Library preparation

[0362] After inactivation of the methyltransferase, the DNA sample may be modified into a form that is compatible for high throughput sequencing. This process maybe referred to as “preparing a sequencing library” or “library preparation”.

[0363] As used herein, unless otherwise indicated, a “sequencing library” refers to a plurality of DNA molecules, each comprising a sequencing adaptor, such as a sequencing adaptor arranged for use in next generation sequencing. Accordingly, references to “preparing a DNA sample into a sequencing library” and “preparing a polynucleotide sample into a sequencing library”, as used herein, unless otherwise indicated, refer to the addition of one or more sequencing adaptors to the DNA molecules of the sample. Thus, the process of preparing a DNA sample into a sequencing library may comprise the ligation of one or more sequencing adapters to the DNA molecules.

[0364] In addition to adaptor ligation, the process of preparing a polynucleotide sample into a sequencing library may comprise end repair and / or A-tailing of the DNA molecules.

[0365] Preferably the process of preparing a sequencing library does not comprise combining the DNA molecules together to form an extended ligated polynucleotide for use, for example, in a sequencing method comprising nanopore technology.

[0366] The reaction mixture comprises a buffer mixture such as the labelling buffer, together with inactive methyltransferase, excess cofactor analogue, and the DNA sample. In general for sequencing applications, library preparation is typically conducted with purified DNA. It has surprisingly been found by the inventors, however, that the library preparation process may be performed directly in the reaction mixture following methyltransferase inactivation and that the efficiency of the library preparation process is not compromised by the use of a different buffer, or the presence of unpurified sample, such as DNA, and / or residual enzyme and cofactor components in the mixture. This finding provides a significant advantage over previous methods, offering

[0367] significant efficiencies in terms of savings of time and reagents. In particular, the finding that any washing procedure may be avoided significantly preserves the level of DNA sample present in the reaction mixture.

[0368] Thus, in such embodiments, the preparation of a sequencing library is preferably performed in a one-pot approach.

[0369] In some embodiments, the method comprises the inactivation of the methyltransferase followed by library preparation without any intervening steps or clean-up process, for example, comprising removal of inactivated enzymes, exchange of reaction buffer, or isolation or purification of the polynucleotide sample. Performing library preparation at this stage, for example, prior to any enrichment process, and without the requirement for any washing steps or clean-up of the sample, surprisingly provides significant processing efficiencies, including significantly reducing any loss of DNA sample.

[0370] The sample maybe subjected to a library preparation process comprising end repair of the DNA sample.

[0371] The end repair process may comprise removal of 3' overhangs, for example using a Klenow fragment-based enzyme. The end repair process may also comprise modifying 3’ ends as necessary to comprise a hydroxyl group.

[0372] The end repair process may additionally or alternatively fill 5' overhangs, for example, using a T4 DNA polymerase. The end repair process may also comprise phosphorylation of 5' ends where necessary, for example, using of a T4 polynucleotide kinase (PNK).

[0373] The DNA sample may be subjected to a library preparation process comprising A-tailing.

[0374] The A-tailing process may comprise the addition of an adenosine residue to the 3' ends of the DNA molecules. This process may reduce the possibility of the DNA moleculesin the sample ligating to each other. The A-tailing process may also increase the rate of adapter ligation, particularly in embodiments in which the adapters comprise a thymine overhang. The A-tailing process may comprise the use of an “exo-Klenow” enzyme.

[0375] In some embodiments, the DNA sample maybe subjected to end repair and A-tailing processes simultaneously. For example, an end repair and A-tailing buffer comprising end repair and A-tailing enzymes may be used.

[0376] The DNA sample maybe subjected to a library preparation process comprising one or more “adapter ligation” processes comprising the ligation of sequencing adapters to the DNA moleculesin the sample.

[0377] The term “adapter” as used herein, unless otherwise specified, refers to a short nucleic acid (such as less than about 500, less than too, or less than about 50 nucleotides in length) that is typically at least partially double-stranded and is attached to either or both ends of a nucleic acid molecule. The adapters may include a primer binding site for segregating each polynucleotide strand, using for example, one or two cycles of PCR. The adapters may include a primer binding site for amplification of the sample. The adapters may include a primer binding site for sequencing applications, such as nextgeneration sequencing (NGS) applications. The adapters may include a binding site for capture probes, such as an oligonucleotide attached to a flow cell support. A plurality of adapters of the same or different sequences may be attached to the DNA molecules in the sample.

[0378] The ligated adapters may include a nucleic acid tag. The nucleic acid tag may be positioned relative to an amplification primer and / or sequencing primer binding site, such that the tag sequence is included in subsequent amplicons and sequence reads. In some embodiments, a plurality of adapters having the same sequence apart from different nucleic acid tags may be attached to the DNA molecules in the sample.

[0379] The ligated adapters may include a barcode that can be introduced at one or both ends of the sample DNA molecule. A “barcode”, “indexing barcode”, or “molecular barcode” as used herein, unless otherwise stated, refers to a nucleic acid molecule comprising a sequence that can serve as a molecular identifier. A barcode maybe a type of nucleic acid tag. For example, individual "barcode" sequences maybe added to the DNA molecules in the sample for use in next-generation sequencing (NGS) so that the sequencing read can be identified and sorted before the final data analysis. In some preferred embodiments, after fractionation (i.e. after step 5), the method may comprisethe incorporation of indexing barcodes, for example, for the purposes of multiplex sequencing.

[0380] The adapter ligation process may comprise the ligation of sequencing adapters to the DNA molecules in the sample. The adapter ligation process may comprise the use of a T4 DNA ligase. Advantageously, any sequencing adapters may be used. Sequencing adapters that have been found to be particularly suitable for use in the disclosed method include, for example, any sequencing adapters suitable for use with high throughout sequencing methods, such as sequencing applications on the Illumina platform. The method may comprise the use of a double-stranded indexing and unique dual indexing (UDI) adapter that enables efficient ligation and identification of PCR amplification replicates in the sequencing dataset. Other adapters may also be used, such as hairpin adapters.

[0381] In some embodiments, the adapter ligation processes may comprise the ligation of adaptors that do not comprise indexing barcodes, and such adaptors may be referred to herein as “stubby adapters”.

[0382] Barcodes may be applied to one or both ends of the DNA molecules as part of the library preparation process. In addition, or alternatively, barcodes may be added to one or both ends of the DNA molecules in a separate amplification step.

[0383] In some preferred embodiments, the library preparation process comprises the ligation of stubby adapters to the polynucleotides, and the subsequent use of primers configured to bind to sequences in the stubby adapters to segregate the polynucleotide strands in exactly one or exactly two cycles of PCR.

[0384] Segregating Polynucleotide Strands

[0385] Segregating each polynucleotide strand in the sample, as shown in Figure 1, has surprisingly been found to provide higher libraiy yield, an increase in average insert size and improved library complexity at regions of high CpG density in the sample.

[0386] The segregation of each polynucleotide strand may comprise the use of a PCR-based method, for example using primers configured to bind to the sequencing adapters that are applied to the polynucleotides during sequencing library preparation. In embodiments in which PCR is used to segregate the strands, preferably exactly one, orexactly two cycles of PCR maybe performed, as the purpose is simply to segregate the epigenetically modified strands, for example, into individual DNA duplexes, as shown in Figure 1, and not to significantly amplify and thereby dilute the proportion of polynucleotide strands that may comprise base modifications.

[0387] As used herein, unless otherwise stated, the terms “segregate”, “segregating”, “segregation”, and similar terms, in relation to the polynucleotides of the sample refer to the separation of the two strands of a duplex polynucleotide. The separated polynucleotide strands may each subsequently be used as a template strand for the formation of a polynucleotide, as shown in Figure 1C. As shown in Figure 1C, the polynucleotide strands Fl, Ri obtained from the original polynucleotide sample may comprise modifications of the nucleotides bases (i.e. an epigenetic modification and / or a tag applied in the preceding steps of the method). In contrast, newly synthesised strands F2, R2 formed using the segregated polynucleotide strands will not include base modifications. After segregation there are no duplex polynucleotides in the sample that comprise base modifications on both strands.

[0388] In some embodiments, segregating each polynucleotide strand comprises segregating each polynucleotide into separate strands. In some embodiments, segregating each polynucleotide strand comprises segregating each polynucleotide strand into a separate new DNA duplex.

[0389] As used herein, unless otherwise stated, the term “DNA duplex” refers to a doublestranded DNA molecule in which the two polynucleotide chains are connected by hydrogen bonds between complementary base pairs.

[0390] The inventors have found that, using previous methods, polynucleotides comprising regions of high CpG density may not be quantitatively represented in the final epigenomic profile, especially when low levels of input sample are used. In particular, duplex polynucleotides comprising regions of dense affinity labelling on both strands have been found to be less well amplified, for example, due to the partial inhibition of PCR, and consequently to be underrepresented in the final epigenomic profile, in some circumstances.

[0391] Segregation of the polynucleotide strands present in the original sample ensures that there are no duplex polynucleotides in the sample that comprise base modifications(i.e. an epigenetic modification or a tag added by the methyltransferase enzyme) on both strands. For example, segregating each polynucleotide strand from the original sample prior to affinity labelling ensures that the affinity label is applied to, at most, only one strand of a duplex. In other examples, each polynucleotide is segregated into a single strand. This prevents the inhibition of subsequent amplification steps by affinity labels on complementary strands of a DNA duplex, for example, by creating a “clean” DNA strand for amplification downstream (e.g. after fractionation). For this reason, the strand segregation step is preferably performed before affinity labelling.

[0392] Including a strand segregation step has been found to provide improved representation of unmethylated genomic regions with very high CpG density in the final epigenomic profile even using low levels (e.g. picogram concentrations) of input DNA.

[0393] Segregating each polynucleotide strand in the sample may comprise performing exactly one cycle of PCR or exactly two cycles of PCR. Preferably, no more than two cycles of

[0394] PCR may be performed for the purposes of strand segregation, in order to avoid significantly amplifying and thereby diluting the proportion of polynucleotide strands in the sample that include any base modification.

[0395] In some preferred embodiments, the primers used to segregate the polynucleotide strands in one or two cycles of PCR are arranged to bind to sequences in stubby adapters that are added to the polynucleotides during the library preparation step.

[0396] In some preferred embodiments, the segregation of each polynucleotide strand using one or two cycles of PCR are performed in the same reaction vessel as the preceding steps (i.e. which may include the steps of applying of a tag using a methyltransferase enzyme, inactivating the enzyme, and the preparation of a sequencing library), without any washing steps or clean-up of the sample.

[0397] Labelling of derivatised DNA

[0398] The method comprises the labelling of derivatised DNA molecules. A methyltransferase is used to bind a tag to unmodified target nucleotides in the DNA sample, and tags on the DNA molecules in the sample may be modified by the addition of an affinity label.

[0399] The affinity label maybe referred to as an “affinity label” or “label” when bound to the tag and an “affinity label precursor” beforehand.

[0400] It has been found that an affinity label may be added to the tag by the addition of the affinity label precursor to the reaction mixture. The finding that an affinity label may be applied to the tag in this technically simple and efficient manner is advantageous in view of the fact that the reaction mixture comprises various components including, inactive methyltransferase, excess cofactor analogue, and the reagents and enzymes required for library preparation and, in some embodiments, strand segregation. The finding that the affinity label may be added to the tag in this way provides a significant advantage over previous methods, by avoiding the requirement for a washing step, thereby providing efficiency savings in terms of time and reagents and avoiding any loss of sample.

[0401] Thus, the method comprises the addition of an affinity label to the tag after library preparation, without any intervening steps or clean-up process, for example, comprising removal of peptides or enzymes, exchange of reaction buffer, or isolation or purification of the sample.

[0402] In some embodiments, binding an affinity label to each tag may comprise adding an affinity label precursor directly into the sequencing library preparation mixture, without a washing step.

[0403] The affinity label may comprise biotin.

[0404] The affinity label precursor maybe a compound of formula (II):

[0405] R9-L4-R10

[0406] (II)

[0407] wherein: R9is a reactive moiety configured to react with a group in the tag and to thereby form a bond therebetween;

[0408] L4is a linker; and

[0409] R10comprises or consists of biotin.

[0410] R9may be an optionally substituted 5 to 30 membered heterocyclyl, an optionally substituted 5 to 30 membered heteroaryl, an optionally substituted C6-3Omembered aryl or an optionally substituted C3-3Ocycloalkyl.

[0411] -5i- A multicyclic group may be understood to be a group comprising two or more fused rings. Accordingly, a multicyclic group may have 2 or 3 fused rings.

[0412] As used herein, a “heterocyclyl”, “heterocyclic” or “heterocycle” group includes non-aromatic saturated or partially saturated mono and multicyclic groups. A heterocyclic ring contains 1 or more heteroatoms in the ring, which may independently selected from nitrogen, oxygen or sulfur. A multicyclic group may be understood to be multicyclic heterocyclyl group if it contains at least one heteroatom and at least one ring which is a non-aromatic saturated or partially saturated ring.

[0413] As used herein, a “cycloalkyl” group includes non-aromatic saturated or partially saturated mono and multicyclic groups. A multicyclic group maybe understood to be multicyclic cycloalkyl group if it only contains carbon atoms in the rings and it contains at least one ring which is a non-aromatic saturated or partially saturated ring.

[0414] As used herein, a “heteroaryl” group includes aromatic mono and multicyclic groups. A heteroaryl ring contains 1 or more heteroatoms in the ring, which may independently selected from nitrogen, oxygen or sulfur. A multicyclic group may be understood to be multicyclic heteroaryl group if it contains at least one heteroatom and every ring is aromatic.

[0415] Preferably, R9contains a triple bond.

[0416] Preferably, R9is an optionally substituted 10 to 20 membered multicyclic heterocyclyl, an optionally substituted 10 to 20 membered multicyclic heteroaryl or an optionally substituted C10-20multicyclic cycloalkyl. R9may be a 14 to 18 membered multicyclic heterocyclyl, an optionally substituted 14 to 18 membered multicyclic heteroaryl or an optionally substituted C13-18multicyclic cycloalkyl.

[0417] In a preferred embodiment,

[0418]

[0419] , wherein X2is N or CH. Preferably, X2is

[0420] L4 may comprise between 1 and 12 groups, each group selected from an optionally substituted hydrocarbon, an optionally substituted polyether chain, NH, O, S or S-S.

[0421] The hydrocarbon may be an optionally substituted alkylene, preferably an optionally substituted C1-10alkylene and more preferably a C1-5alkylene. The alkylene may be substituted with an OH or oxo group. Preferably, the alkylene is substituted with an oxo group.

[0422] The optionally substituted polyether chain may be an optionally substituted polyethylene glycol chain. The polyethylene glycol chain may comprise up to 15 monomers, up to 10 monomers or up to 5 monomers of ethylene glycol.

[0423] Accordingly, may have the structure

[0424] -L5-L6-I -L8-*,

[0425] wherein IA to L8are each independently absent or an optionally substituted hydrocarbon, an optionally substituted polyether chain, an NH, O, S or S-S; and an asterisk indicates a point of bonding to R10.

[0426] In some embodiments, IA is an optionally substituted hydrocarbon. Accordingly, L5may be COCH2CH2.

[0427] In some embodiments, L6is NH.

[0428] In some embodiments, L7is an optionally substituted hydrocarbon. Accordingly,

[0429]

[0430] may be COCH2CH2.

[0431] In some embodiments, L8is an optionally substituted polyether chain. The optionally substituted polyether chain may be an optionally substituted polyethylene glycol chain.

[0432] The polyethylene glycol chain may comprise up to 15 monomers, up to 10 monomers or up to 5 monomers of ethylene glycol. Accordingly, L8may be (OCH2CH2)r, where r is an integer between 1 and 15, more preferably between 2 and 10 or between 3 and 5. In some embodiments, r is 4.

[0433] Accordingly, U may

[0434]

[0435] L4 may have no charge.

[0436] Negatively charged linkers have been found to react poorly with the tag. Preferably, IA is not negatively charged.

[0437] R10may have the following formula:

[0438] R11-(CH2)S-L9-

[0439] wherein R11is biotin

[0440] s is an integer between 1 and 8; and

[0441] L9is absent or is COO or CONH.

[0442] Sulfonated linkers have been found to react particularly poorly with the tag. Preferably, L4 and R10are not sulfonated.

[0443] Preferably, the affinity label precursor is not DBCO-SS-biotin. Preferably, the affinity label precursor is not NHS-SS-biotin.

[0444] A modified tagged cytosine residue, which comprises the affinity label, may be understood to have the following structure:

[0445]

[0446] wherein IA and R10are as defined above; and

[0447] L10is a linker.

[0448] L10may be understood to be -CH2-U-[L3]m-[HM]n-[L2]p-L11-, wherein U, L2, IA, HM, m, n and p are as defined above and L11is a linker formed due to a reaction between the R6and R9groups.

[0449] Accordingly, L11may

[0450]

[0451] asterisk indicates a point of bonding to L4and X2is as defined above.

[0452] The present inventors have surprisingly found that in previous methods, such as that described by Kriukiene et al. (Nature Communications 20134:2190), DNA fragments having a significant density of CpG sites, such as, for example, 5 or more CpG sites per 100 bp, may be underrepresented in the sequencing reads, thereby introducing bias to the results.

[0453] An advantage of the disclosed method is that if a purification process, such as DNA isolation, is performed at this point, it is the only clean-up step for the entire process, and this has been found to dramatically improve the efficiency and sensitivity of the process. This is made possible, firstly, by the inactivation of the methyltransferase and, secondly, the surprising finding that the enzymes used for library preparation exhibit high levels of activity in the resulting buffers, which are significantly different to the buffer mixtures designed for use in library preparation.

[0454] Thus, in some embodiments, the method may comprise, after the affinity labelling step (step 4), and before the fractionation step (step 5), a step of purifying the DNA.

[0455] Preferably the method involves no more than one step of purifying the DNA.

[0456] Any suitable method for purifying the DNA may be used. For example, DNA may be purified using a DNA purification kit. The DNA may be washed, for example, using ethanol, such as 80% ethanol, or other DNA washing buffer. After washing, the DNA may be eluted, for example, using a suitable elution buffer, such as phosphate buffer.

[0457] Fractionation

[0458] The method comprises, after the labelling of derivatised polynucleotides (step 4), fractionating the derivatised polynucleotides of the sequencing library into first and second fractions. The first fraction is enriched for polynucleotides comprising an affinity label, and the second fraction is enriched for polynucleotides lacking an affinity label.

[0459] In some embodiments, fractionation may comprise the use of the affinity label, such that polynucleotides comprising an affinity label are separated, using the affinity label, from polynucleotides lacking an affinity label. As a result, the first fraction is enriched for polynucleotides comprising an affinity label, in the sense that substantially or entirely all of the polynucleotides in the first fraction comprise an affinity label.

[0460] Similarly, the second fraction is enriched for polynucleotides lacking an affinity label, in the sense that substantially or entirely all of the polynucleotides in the second fraction lack an affinity label.

[0461] The fractionation may comprise selectively isolating the labelled polynucleotides using the affinity label. For example, fractionation of the polynucleotides may comprise binding of the affinity label to a capture probe that specifically binds to the affinity label.

[0462] In embodiments in which the affinity label comprises biotin, fractionation of the polynucleotides may comprise selectively isolating the labelled polynucleotides using a biotin-binding protein.

[0463] The biotin-binding protein may comprise, for example, streptavidin, avidin, and / or a biotin-specific antibody.

[0464] The biotin-binding protein may comprise streptavidin, or a functional analogue or derivative of streptavidin.

[0465] The biotin-binding protein may comprise a separation medium or substrate. For example, the biotin-binding protein maybe conjugated to a surface. The surface may comprise a plurality of microbeads, such as paramagnetic microbeads.

[0466] In embodiments in which the separation medium or substrate comprises a plurality of microbeads coated with biotin-binding protein, the method may comprise binding the labelled polynucleotides to the biotin-binding protein on the coated microbeads and then isolating the coated microbeads. Isolation of the microbeads maybe performed by centrifugation. In embodiments comprising the use of paramagnetic microbeads, isolation of the microbeads may comprise the application of a magnetic field to the reaction mixture to separate the beads from the remainder of the suspension.

[0467] The biotin-binding protein may comprise streptavidin conjugated to the surface of microbeads. Preferably the streptavidin-coated microbeads maybe streptavidin-coated paramagnetic microbeads.

[0468] After an appropriate incubation to bind the labelled polynucleotides to the capture probe, the probe may be washed to remove unbound and non-specifically bound polynucleotides. In embodiments in which the affinity label comprises biotin, the biotin-binding protein may be washed by any suitable method to remove unbound and non-specifically bound polynucleotides.

[0469] After the selective isolation of the labelled polynucleotides, the polynucleotides are separated from the capture probe.

[0470] In previous methods, such as that described by Kriukiene et al. (Nature Communications 20134:2190), DNA fragments are released from a streptavidin capture agent using oxidative cleavage of a disulfide bond within the affinity label. However, this method has been found by the present inventors to be inconsistently reproducible and to have poor efficiency.

[0471] In the disclosed method, the polynucleotides are preferably not separated from the capture probe by a method comprising oxidative cleavage of the tag or affinity label.

[0472] Thus, in some embodiments, the method does not comprise the separation of the polynucleotides from the capture probe by cleavage, such as oxidative cleavage or hydrolysis, of the tag or affinity label.

[0473] In some embodiments, the method may comprise the denaturation of the capture probe. For example, in embodiments in which the capture probe comprises a biotin-binding protein, the method may comprise the denaturation of the biotin-binding protein. This method has been found to be particularly advantageous due to the consistent release of DNA fragments regardless of the number of the attached affinity labels.

[0474] The ability of streptavidin to bind to biotin is dependent on both a sterically defined binding pocket and the highly polar residues within it. Any agent that induces a

[0475] conformational change of streptavidin may, therefore, be used to release the labelled polynucleotides. The inventors have found that, in embodiments in which the biotinbinding protein comprises streptavidin, the labelled polynucleotides maybe released from the streptavidin by any method that denatures streptavidin without damaging the polynucleotides.

[0476] In some embodiments, the labelled polynucleotides may be released from the streptavidin by incubation in pure water at a temperature of about 7O°C.

[0477] In some embodiments, the labelled polynucleotides may be released from the streptavidin by incubation in 12-15% (v / v) phenol at room temperature.

[0478] In some embodiments, streptavidin may be denatured using a denaturing reagent, such as 1% sodium dodecyl sulphate and heating the sample to 9O°C.

[0479] Advantageously, because the affinity label is not damaged by this method comprising the denaturation of streptavidin, the first fraction may be further enriched for polynucleotides comprising an affinity label by repeating the selective isolation (affinity purification) step in one or more further cycles.

[0480] Sequencing

[0481] The inventors have found that, using the disclosed method, target unmodified nucleotides, such as unmodified CpG dinucleotides, in the polynucleotide sample are derivatised in such a way that they may be isolated and subsequently sequenced without bias. Thus, the first fraction may be used with extremely low sample quantities to provide a highly accurate epigenetic profile.

[0482] Following fractionation, the polynucleotides of the first and / or second fraction may be amplified. Amplification may be used to simultaneously introduce indexing barcodes to the polynucleotides.

[0483] Sequencing the polynucleotides of the first and / or second fraction may comprise pooling the first and second fractions and sequencing them together. In such embodiments, the first and second fraction may be distinguished using indexing barcodes.

[0484] The inventors have surprisingly found that standard DNA polymerases are able to amplify densely modified DNA comprising the disclosed affinity labels, prior to sequencing. Moreover, this has advantageously been found to be possible under the conditions employed for DNA release. This negates the need for DNA purification prior to amplification.

[0485] The polynucleotides may be amplified by PCR or qPCR, for example, using primers designed to anneal within the ligated sequencing adapters, and an appropriate PCR program.

[0486] The amplification method may be arranged to introduce indexing barcodes into the polynucleotides. For example, in some embodiments, the method may comprise amplification before fractionation to introduce indexing barcodes into the polynucleotides. In some embodiments, the method may comprise amplification after fractionation to introduce indexing barcodes into the polynucleotides of the first and / or second fraction.

[0487] The amplified polynucleotides maybe purified prior to sequencing by any suitable method for cleaning up PCR products for use in a sequencing platform.

[0488] The amplified polynucleotides may be used directly for sequencing without further purification.

[0489] The term “sequencing” as used herein, unless otherwise indicated, refers to any method that may be used to determine the sequence (i.e. the order of nucleotides) in a nucleic acid such as DNA or RNA.

[0490] Any type of sequencing platform may be used to determine the sequences of the polynucleotides, in combination with the appropriately ligated sequencing adapter. Thus, sequencing approaches that may be suitable for use in the disclosed method include, but are not limited to, Sanger sequencing, high-throughput sequencing, pyrosequencing, sequencing-by-synthesis, single-molecule sequencing, nanoporebased sequencing, semiconductor sequencing, sequencing-by-ligation, sequencing-by-hybridization, RNA-Seq (Illumina), Digital Gene Expression (Helicos), next generation sequencing (NGS), Single Molecule Sequencing by Synthesis (SMSS) (Helicos), massively-parallel sequencing, Clonal Single Molecule Array (Solexa), shotgun

[0491] sequencing, Ion Torrent, Oxford Nanopore, Roche Genia, Maxim-Gilbert sequencing, primer walking, sequencing using Singular Genomics, Ultima Genomics, Element Biosciences, PacBio, SOLiD, Ion Torrent, or Nanopore platforms. Sequencing reactions can be performed in a variety of sample processing units, which may include multiple lanes, multiple channels, multiple wells, or other means of processing multiple sample sets substantially simultaneously.

[0492] The method may comprise a high throughput sequencing method. The terms “next generation sequencing”, “NGS”, and “high throughput sequencing” as used herein, refer to sequencing technologies having increased throughput as compared to traditional

[0493] Sanger- and capillary electrophoresis-based approaches. The high throughput sequencing method may be capable of generating hundreds of thousands of sequence reads in parallel. The method may comprise a multiplex sequencing technique. The high throughput sequencing methods that may be used include, but are not limited to, sequencing by synthesis, sequencing by ligation, and sequencing by hybridization. The sequencing method maybe capable of sequencing single molecules.

[0494] In some embodiments, the method comprises sequencing the polynucleotides using the Illumina platform.

[0495] The method may comprise comparing the sequencing reads to a reference sequence comprising the target marker region. The method may comprise comparing the sequencing reads to a reference genome to determine the genomic location of the sequencing reads. The reference sequence may be a human genome, or may comprise one or more portions thereof, such as one or more chromosomes and / or chromosomal regions.

[0496] Any suitable alignment method for aligning the sequencing reads to the reference sequence that compatible with high throughput sequencing data may be used, for example, using the Burrows Wheeler Alignment algorithm.

[0497] Aligned reads may be normalised. Any method of normalisation used in the art may maybe used. For example, normalising the sequencing reads may comprise reporting the number of reads in an aligned region (bin) as a fraction of reads per million reads of the sequencing output.

[0498] - 6o -

[0499] The method may comprise comparing the normalised read counts from two or more sequencing experiments.

[0500] In some embodiments, obtaining the modification status of nucleotide residues in the target marker region of the polynucleotide sequence may comprise comparing the sequences of the sequencing reads of the first and / or second fraction to a reference sequence comprising the target marker region to determine the location of the sequencing reads within the reference sequence and thereby the presence or otherwise of unmodified nucleotide residues at specific locations within the target marker region.

[0501] In some embodiments, obtaining the modification status of nucleotide residues in the target marker region of the polynucleotide sequence comprises obtaining a profile of the modification status of nucleotide residues in the target marker region of the polynucleotide sequence. In such embodiments, the method may comprise comparing the sequences of the sequencing reads of the first and / or second fraction to a reference sequence comprising the target marker region to determine the location of the sequencing reads within the reference sequence and thereby the presence or otherwise of unmodified nucleotide residues at specific locations within the target marker region.

[0502] Hence, in some embodiments, there is provided a method for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample from a subject, the method comprising:

[0503] (1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in the sample, wherein each unmodified nucleotide residue is unmodified in the target position;

[0504] (2) inactivating the methyltransferase;

[0505] (3) preparing the sample into a sequencing library;

[0506] (4) binding an affinity label to each tag;

[0507] (5) fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and

[0508] (6) sequencing the polynucleotides of the first and / or second fraction to obtain the modification status of nucleotide residues in a target marker region of the polynucleotide sequence,

[0509] wherein obtaining the modification status of nucleotide residues in a target marker region of the polynucleotide sequence comprises comparing the sequences ofthe sequencing reads of the first and / or second fraction to a reference sequence comprising the target marker region to determine the location of the sequencing reads within the reference sequence and thereby the presence or otherwise of unmodified nucleotide residues at specific locations within the target marker region,

[0510] wherein the target marker region of the polynucleotide sequence is a region that has a characteristic epigenetic modification pattern in the specific tissue or cell type that is indicative of the specific tissue or cell type, and

[0511] wherein the detection of the characteristic epigenetic modification pattern in the modification status information identifies DNA from the specific tissue or cell type in the sample.

[0512] In some embodiments, the method may comprise the detection of unmodified cytosine residues in CpG dinucleotides of a DNA sample. The terms “CpG”, “CpG site”, and “CpG dinucleotide”, are used interchangeably herein to refer to a cytosine-phosphate-guanine sequence in a 5’ to 3’ direction in the backbone of a nucleic acid.

[0513] The terms “CpG modification status” and “modification status” as used interchangeably herein, unless otherwise stated, refer to the presence (modified) or absence (unmodified) of any chemical modification at the C5 position of cytosine within one or a plurality of CpG dinucleotides.

[0514] Thus, in some embodiments, the method may comprise preparing a profile of the modification status at the cytosine C5 position of CpG dinucleotides, wherein the method further comprises comparing the sequences of the sequencing reads of the first fraction to a reference sequence to determine the location of the sequencing reads within the reference sequence and thereby the presence or otherwise of unmodified cytosine residues in specific CpG dinucleotides within the reference sequence.

[0515] In embodiments in which the method comprises determining, for a plurality of CpG dinucleotides, the presence (modified) or absence (unmodified) of any chemical modification at the C5 position of each of the plurality of cytosines, the “CpG modification status” and “modification status” may also be referred to as the “profile”.

[0516] In accordance with a second aspect there is provided a kit for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample from a subject, the kit comprising:

[0517] 1. a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag from a cofactor analogue to each unmodified nucleotide residue in the DNA sample, wherein each unmodified nucleotide residue is unmodified in the target position;

[0518] 2. an affinity label precursor suitable for binding an affinity label comprising a biotin to the tags; and / or

[0519] 3. instructions for how the kit is to be used in accordance with the method of the first aspect.

[0520] In some embodiments, the kit may comprise:

[0521] 1. a methyltransferase enzyme configured to modify the cytosine C5 position of a CpG dinucleotide to apply a tag from a cofactor analogue to each unmodified cytosine residue in the DNA sample, wherein each unmodified cytosine residue is the cytosine of a CpG dinucleotide that is unmodified in the C5 position;

[0522] 2. an affinity label precursor suitable for binding an affinity label to the tags, wherein the affinity label comprises biotin; and / or

[0523] 3. instructions for how the kit is to be used in accordance with the method of the first aspect.

[0524] In some embodiments, the kit may further comprise a capture agent comprising a biotin-binding protein for fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for DNA molecules comprising an affinity label, and wherein the second fraction is enriched for DNA molecules lacking an affinity label.

[0525] In some embodiments, the kit may further comprise a cofactor analogue comprising the tag precursor.

[0526] In some embodiments, the kit may further comprise sequencing adaptors for preparing the DNA into a sequencing library, as described in accordance with the first aspect. The kit may further comprise enzymes and reagents for reverse transcription, end repair, A-tailing, and / or adapter ligation, as described in accordance with the first aspect.

[0527] In some embodiments, the kit may or may not comprise a capture agent comprising a biotin-binding protein for fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for polynucleotides comprising an

[0528] affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label.

[0529] In some embodiments, the kit may further comprise a releasing agent for releasing the affinity label from the capture agent by denaturation of the biotin-binding protein.

[0530] In some embodiments, the kit may comprise:

[0531] 1. a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag from a cofactor analogue to each unmodified nucleotide residue in the DNA sample, and a cofactor analogue comprising the tag precursor, wherein each unmodified nucleotide residue is unmodified in the target position;

[0532] 2. sequencing adaptors and enzymes for preparing the DNA into a sequencing library;

[0533] 3. an affinity label precursor suitable for binding an affinity label comprising a biotin to the tags

[0534] 4. a capture agent comprising a biotin-binding protein for fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for DNA molecules comprising an affinity label, and wherein the second fraction is enriched for DNA molecules lacking an affinity label;

[0535] 5. a releasing agent for releasing the affinity label from the capture agent by denaturation of the biotin-binding protein; and / or

[0536] 6. instructions for how the kit is to be used in accordance with the method of the first aspect.

[0537] The kit may be suitable for use in or as a one pot method as described in accordance with the first aspect.

[0538] The methyltransferase enzyme may be a methyltransferase as described in accordance with the first aspect.

[0539] The cofactor analogue may be a cofactor analogue as described in accordance with the first aspect. The cofactor analogue may be synthetic methyltransferase cofactor analogue. The cofactor analogue may comprise a compound of formula (I).

[0540] The sequencing adaptors and enzymes for preparing the polynucleotide into a sequencing library may comprise enzymes and reagents for reverse transcription, endrepair, A-tailing, and / or adapter ligation, as described in accordance with the first aspect.

[0541] The affinity label precursor maybe an affinity label precursor as described in accordance with the first aspect. The affinity label precursor may comprise a compound of formula (II).

[0542] The capture agent comprising a biotin-binding protein for fractionating the sequencing library maybe as described in accordance with the first aspect.

[0543] The releasing agent for releasing the affinity label from the capture agent by denaturation of the biotin-binding protein may be as described herein.

[0544] All features described herein (including any accompanying claims and drawings), and / or all of the steps of any method or process so disclosed, may be combined with any of the above aspects in any combination, except combinations where at least some of such features and / or steps are mutually exclusive.

[0545] The invention will now be illustrated by reference to specific Examples showing how embodiments may be carried into effect, which are not intended to be limiting. Data from the Examples is presented in the Figures, in which:

[0546] Figure 1A is a flow chart showing the disclosed method.

[0547] Figure 1B is a diagram providing an overview of the concept of the disclosed method. Cell-free DNA that has previously been obtained from a subject is derivatised by treatment with a CpG-targeting methyltransferase (in this case M.MpeI) and a synthetic cofactor analogue (in this case ETA-AdoHcy-N3) that results in the addition of tags at unmodified CpG sites. The methyltransferase is inactivated and the DNA fragments are then end-repaired and ligated to sequencing adapters. Fragments comprising a tag are subsequently labelled by attaching an affinity label (for example, biotin) to the tag, and isolated (for example, using streptavidin-coated magnetic beads). Thus, tagged (unmodified CpG sites) and untagged (predominantly 5mCpG and 5hmCpG sites) can be fractionated to form the first (labelled) and second (unlabelled) fractions, and separately amplified and sequenced. The sequencing reads of the first fraction in particular may be used to obtain the modification status of nucleotide

[0548] residues in a target region that has a characteristic epigenetic modification pattern that is indicative of a specific tissue or cell type of interest (i.e. a target marker region). The detection of the characteristic epigenetic modification pattern in the modification status information identifies DNA from the specific tissue or cell type in the sample.

[0549] Figure 1C is a diagram illustrating an embodiment of the disclosed method comprising the segregation of the polynucleotide strands of a duplex polynucleotide in a sample (e.g. cfDNA) into two separate new DNA duplexes, such that the new duplexes each contain one of the original polynucleotide strands. “Fl” and “Ri” are the original forward and reverse strands respectively of a duplex DNA fragment in the polynucleotide sample. “F2” is a new strand, synthesised using one PCR cycle, that has a sequence complementary to that of the original forward strand, and “R2” is the new synthesised strand that has a sequence complementary to that of the original reverse strand. “Me-C” represents methylated cytosine, “MeOH-C” represents 5-hydroxymethylated cytosine, and “TAG-C” represents unmethylated cytosine in a CpG context that has been derivatised as described herein prior to segregation. All other bases are unmodified. Whereas both strands F1 and R1 of the original polynucleotide duplex comprise base modifications (i.e. epigenetic modifications and a derivatised cytosine), the newly synthesised strands F2, R2 do not, and thus each of the new DNA duplexes formed after segregation contains only one strand comprising base modifications. Thus, the base-modified polynucleotide strands of the original duplex are segregated into two separate new DNA duplexes. Copying the DNA before the affinity tag is introduced thus creates a ‘clean’ DNA strand for amplification after fractionation.

[0550] Figure 2 shows signal from unmethylome profiles of specific tissues generated using the disclosed method, at regions identified as cell-type-specific methylation markers by Loyfer et al using bisulfite sequencing (Nature, 613, 355-364). These uniquely unmethylated regions are highly enriched in the profiles produced by the disclosed method and show signal that is specific to the tissue of interest. This allows the presence of DNA from a specific tissue or cell type in cfDNA to be identified. The cell types are as follows: 1 - blood (granulocyte); 2 - gastric epithelial; 3 - colon epithelial;

[0551] 4 - liver hepatocytes; 5 - breast (luminal); 6 - lung epithelial alveolar.

[0552] Figure 3 is a PCA plot showing clear separation of different tissue types clustered using cell type specific unmethylated marker regions (defined by Loyfer et al. Nature,613, 355–364). Colon, breast and lung cancer samples are from tissue stored in FFPE blocks.

[0553] Figure 4 shows signals generated using the disclosed method across 33 patient samples at cell type specific unmethylated marker regions (defined by Loyfer et al.

[0554] Nature, 613, 355-364). Patient samples are from tumour (FFPE blocks for (A) colon cancer, (B) lung cancer, (C) breast cancer, and for (D) blood (buffy coat)). The cell typespecific markers are as follows: 1 - colon, gastric, and small intestine; 2 - colon and small intestine; 3 - lung (alveolar); 4 - lung (alveolar) and bronchial; 5 - breast (basal); 6 - breast (luminal); 7 - blood (granulocyte); 8 - blood (monocyte and macrophage); 9 - blood (T lymphocytes); 10 - blood (B lymphocytes).

[0555] Figure 5 is a plot highlighting the specificity of uniquely unmethylated regions in a given cell type. Unmethylated regions are shown in rows and are determined using the disclosed profiling method for genomic DNA extracted from each cell line. In columns, the Figure shows the signal from unmethylated DNA reads in each of these regions for a mixture of DNA from the four cell types described. Clear and specific signal, showing a significant improvement in signal:noise compared to the markers identified by Loyfer et al using bisulfite sequencing (Nature, 613, 355-364) is observed for each cell line in the mixture.

[0556] Figure 6 shows the detection of tissue injury using an epigenetic profile generated using the disclosed method from a cfDNA sample. Specifically, a cfDNA signature of chronic pulmonary disease (CPD) is shown. The bars indicate the percentage increase of DNA from specific cell-types, in cfDNA from chronic pulmonary disease patients, across four tissues, generated by quantifying signal in cell-type specific marker regions. Note that renal failure is commonly associated with COPD and is clearly detected by the assay in this cohort.

[0557] Figure 7 shows signals generated using the disclosed method for unmethylated marker regions identified for 16 different mouse tissues. The columns show samples grouped by tissue type and the rows show marker regions grouped by tissue type. The tissue types are as follows: 1 - blood (pbmc); 2 - spleen; 3 - brain; 4 - oesophagus; 5-stomach; 6 - pancreas; 7 - liver; 8 - intestine; 9 - colon; 10 - kidney; 11 - lung; 12 -heart; 13 - skeletal muscle; 14 - skin; 15 - testis; 16 - placenta.

[0558] Figure 8 is a graph comparing the detection of markers of liver damage in the blood of mice treated with paracetamol. The pale unbroken line and circular points show the level of detection of unmethylated marker regions indicative of liver-derived DNA in cfDNA samples using the disclosed method (left-hand y-axis), and the dark dotted line and square points show the level of detection of the protein biomarker alanine aminotransferase (ALT; right-hand y-axis).

[0559] Figure 9 shows signals generated using the disclosed method for unmethylated marker regions identified for 16 different rat tissues. The columns show samples grouped by tissue type and the rows show marker regions grouped by tissue type. The tissue types are as follows: 1 - blood (pbmc); 2 - spleen; 3 - brain; 4 - oesophagus; 5-stomach; 6 - pancreas; 7 - liver; 8 - intestine; 9 - colon; 10 - kidney; 11 - lung; 12 -heart; 13 - muscle; 14 - skin; 15 - testis; 16 - placenta.

[0560] Figure 10 shows a number of graphs comparing the detection of markers of bleomycin-induced tissue damage in rats. Figure 10A shows graphs of lung injury score and lung fibrosis score measured by conventional histopathogy at different time points post-treatment (o, 1, 2, 3, 10, and 28 days). For each timepoint the left-hand bars show the vehicle-treated samples and the right-hand bars show the bleomycin-treated groups. Figure 10B shows the level of detection (cumulative signal) of unmethylated marker regions indicative of lung-derived DNA in cfDNA samples using the disclosed method at the same time points as in Figure 10A. Figures 10C and 10D show the level of detection (cumulative signal) of unmethylated marker regions indicative of heart muscle-derived DNA (Figure 10C) and pancreas-derived DNA in cfDNA samples using the disclosed method, also at the same time points. Figures 10B-D are based on the signal at the top 100 discriminatory tissue-specific markers.

[0561] Figure 11 shows signals generated using the disclosed method for unmethylated marker regions identified for 11 healthy human cell types. Samples were taken from five individuals. The columns show samples grouped by tissue and cell type and the rows show marker regions grouped by tissue and cell type. The tissue and cell types are as follows: 1-4 blood (1 - CD19+ B cells; 2 - CD4+ T cells; 3 - CD8+ T cells; 4 -neutrophils); 5 heart (cardiomyocytes); 6-8 liver (6 - hepatocytes; 7 - Kupffer; 8 -endothelial); 9-11 lung (9 - endothelial; 10 - epithelial; 11 - fibroblast).

[0562] Examples

[0563] The disclosed method combines a procedure of DNA library preparation for next generation sequencing and a method for labelling unmodified, such as epigenetically unmodified, nucleotides. Using the label, the DNA library is subsequently fractionated into modified and unmodified fractions. The method has been found to be highly sensitive and advantageously minimises the number of DNA purification steps required and is highly efficient. As a result, the disclosed enzymatic platform can be applied at DNA concentrations that are compatible with single-cell analysis (picogram inputs).

[0564] The inventors have advantageously found that due to the remarkable sensitivity of the disclosed approach, it may be used as a platform for the identification of DNA from a specific tissue or cell type in a cfDNA sample, for example for diagnosing disease or other damage to a specific tissue or cell type.

[0565] A flow chart of the disclosed method is shown in Figure 1A and an overview of an embodiment of the disclosed method is shown schematically in Figure 1B.

[0566] In the embodiment shown in Figure 1B, a bacterial DNA methyltransferase enzyme (M.MpeI) is used to target unmodified CpG sites for modification with an unnatural cofactor analogue of S-adenosyl-L-methionine referred to herein as ETA-AdoHcy-N3.

[0567] Incubation of the methyltransferase, DNA and cofactor for one-hour results in complete modification of the target DNA, which is functionalised with azide-terminating tags. After strand segregation, these tags can be further modified (for example, biotinylated) to enable fractionation of modified and unmodified DNA (where ‘unmodified’ refers to all genomic DNA fragments containing one or more CpG dinucleotide that is unmodified (for example, that is not methylated, hydroxymethylated, carboxylated, or acylated) at the C5-position).

[0568] As shown in Figure 1C, in some embodiments, each polynucleotide strand in the sample may be segregated using a small number of cycles of DNA replication (such as 1, 2, or 3 cycles, for example). Including a strand segregation step in the disclosed method has been found to provide reproducible epigenetic modification status information for regions of very high CpG density even using the very low levels (e.g. picogram concentrations) of DNA derived from a specific tissue or cell type that may be present in a cfDNA sample.

[0569] Example 1

[0570] To test whether the disclosed method may be used to identify the originating tissue of DNS in a cfDNA sample from an individual, cfDNA samples were profiled using the disclosed method and analysed for the presence of markers of specific tissue or cell types. The markers used were those previously identified by Loyfer et al using bisulfite sequencing (Nature, 613, 355-364). The presence of markers of the following tissue and cell types was assessed: 1 - blood (granulocytes); 2 - gastric epithelial cells; 3 -colon epithelial cells; 4 - liver hepatocytes; 5 - breast (luminal cells); 6 - lung epithelial alveolar cells.

[0571] As shown in Figures 2 and 3, the markers were detectable in the samples and found to be highly specific for the identification of each tissue or cell type.

[0572] Example 2

[0573] To test application of the approach for the identification of tissue-of-origin of DNA in a tissue or blood sample, samples derived from patient tumours or blood were profiled. Signal for the patient samples was assessed in regions previously identified by Loyfer et al using bisulfite sequencing (Nature, 613, 355-364). In all cases where DNA was extracted from patient samples, it was possible to identify the originating tissue type by simple enumeration of the signal at cell-type specific marker regions (see Figures 3 and 4).

[0574] Example 3

[0575] The inventors surprisingly found that improved tissue-specific, unmethylated DNA markers may be identified using unmethylome profiles produced using the disclosed method.

[0576] To identify regions specifically unmethylated in a given tissue or cell type, the inventors prepared genome-wide profiles of unmethylated DNA enriched using the disclosed platform for each of four different tissue and cell types (as shown in Figure 5).

[0577] The profile for each tissue or cell type was then compared to the profile of each of the other tissue or cell types to identify regions that were most discriminatory - i.e. those regions that were highly unmethylated in the subject tissue or cell type but highly methylated in the profiles of the other tissue or cell types. In this way, regions of the genome having a characteristic, highly discriminatory, methylation profile for a giventissue or cell type were identified. Typically, regions having a length of about 120-1000bp were found to be advantageous.

[0578] The one thousand most discriminative regions for each individual tissue or cell type were compiled to produce the atlas shown in Figure 5, which shows the signal in the profiles of DNA from three individual samples (columns) for each of the atlas marker regions (rows).

[0579] As shown in Figure 5, the identified unmethylated regions are highly specific for each tissue or cell type and may be used to determine the origin of DNA from different tissues and cell types as shown.

[0580] Example 4

[0581] Blood was collected from patients with a diagnosis of chronic obstructive pulmonary disease (COPD). Change in signal in regions specific to lung-derived cell types was assessed against a cohort of healthy patients.

[0582] Example 5 - Preparation of Mouse Atlas

[0583] Tissue-specific, unmethylated DNA markers were identified using DNA extracted from sixteen mouse tissues (as shown in Figure 7: 1 - blood (pbmc); 2 - spleen; 3 - brain; 4

[0584] - oesophagus; 5- stomach; 6 - pancreas; 7 - liver; 8 - intestine; 9 - colon; 10 - kidney; 11 - lung; 12 - heart; 13 - skeletal muscle; 14 - skin; 15 - testis; 16 - placenta).

[0585] To identify regions specifically unmethylated in a given tissue or cell type, the inventors prepared genome-wide profiles of unmethylated DNA enriched using the disclosed platform for each of the sixteen different tissue and cell types. The profile for each tissue or cell type was then compared to the profile of each of the other tissue or cell types to identify regions that were most discriminatory - i.e. those regions that were highly unmethylated in the subject tissue or cell type but highly methylated in the profiles of the other fifteen tissue or cell types. In this way, regions of the genome having a characteristic, highly discriminatory, methylation profile for a given tissue or cell type were identified. Typically, regions having a length of about 120-1000bp were found to be advantageous.

[0586] The hundred most discriminative regions for each individual tissue or cell type were compiled to produce the atlas shown in Figure 7, which shows the signal in the profilesof DNA extracted from three individual mice (columns) for each of the atlas marker regions (rows).

[0587] As shown in Figure 7, the identified unmethylated regions are highly specific for each tissue or cell type.

[0588] Example 6 - Detection of tissue damage using Mouse Atlas

[0589] Paracetamol is well known for its hepatotoxicity when taken in high doses. To test whether liver damage induced by paracetamol overdose may be detected in mice through cfDNA methylation profiling, the inventors evaluated the performance of the mouse atlas for the detection of liver damage in comparison to standard protein biomarkers of liver health and function, ALT (alanine aminotransferase) and AST (aspartate aminotransferase). When liver cells are damaged, inflamed, or die, the liver enzymes ALT and AST leak into the bloodstream, and thus the detection of an increased concentration of these markers is indicative of liver damage and compromised liver function.

[0590] Mice were administered a high dose of paracetamol, with blood samples collected at four timepoints: pre-dose, and 1, 4, and 8 hours post-exposure. Vehicle-treated mice served as negative controls. Each timepoint included five biological replicates.

[0591] Using the disclosed method and the mouse altas prepared as described in Example 5, liver-derived DNA was detectable in the 4 hours post-treatment group, the same timepoint at which ALT was detectable. The variability in the signal between groups, however (reflected in the size of the error bars in Figure 8) was significantly reduced using the disclosed method.

[0592] Figure 8 shows that the signal using the mouse atlas regions are highly performant, relative to the current testing paradigm, which shows significantly more signal variability than the disclosed atlas-based approach.

[0593] Example 7 - Preparation of Rat Atlas

[0594] Tissue-specific, unmethylated DNA markers were identified using DNA extracted from sixteen rat tissues (as shown in Figure 9: 1- blood (pbmc); 2 - spleen; 3 - brain; 4 -oesophagus; 5- stomach; 6 - pancreas; 7 - liver; 8 - intestine; 9 - colon; 10 - kidney;

[0595] 11 - lung; 12 - heart; 13 - skeletal muscle; 14 - skin; 15 - testis; 16 - placenta).

[0596] To identify regions specifically unmethylated in a given tissue or cell type, the inventors prepared genome-wide profiles of unmethylated DNA enriched using the disclosed platform for each of the sixteen different tissue and cell types. The profile for each tissue or cell type was then compared to the profile of each of the other tissue or cell types to identify regions that were most discriminatory - i.e. those regions that were highly unmethylated in the subject tissue or cell type but highly methylated in the profiles of the other fifteen tissue or cell types. In this way, regions of the genome having a characteristic, highly discriminatory, methylation profile for a given tissue or cell type were identified. Typically, regions having a length of about 120-1000 nucleotides were found to be advantageous.

[0597] The hundred most discriminative regions for each individual tissue or cell type were compiled to produce the atlas shown in Figure 9, which shows the signal in the profiles of DNA extracted from three individual rats (columns) for each of the atlas marker regions (rows).

[0598] As shown in Figure 9, the identified unmethylated regions are highly specific for each tissue or cell type.

[0599] Example 8 - Detection of tissue damage using Rat Atlas

[0600] It is well established that Bleomycin, a chemotherapeutic antibiotic, induces pulmonary fibrosis in rodents. The inventors aimed to use this animal model to evaluate the capacity of the disclosed method to detect drug-induced toxicity in preclinical models.

[0601] A rat atlas compiled using the approach described in Example 7, comprising the 100 most discriminative regions for each individual tissue type, was used in this study.

[0602] Tissue damage was quantified using the rat atlas and the results evaluated in the context of expected toxicity.

[0603] As shown in Figure 10A, histology confirmed that the bleomycin-treated rats from the terminal study exhibit gradual lung damage peaking at 10 days, with a slight recovery observed after 28 days. These rats also show significant lung fibrosis at 10 and 28 days.

[0604] Figure 10B shows that profiles produced using the disclosed method detect elevated concentrations of lung-derived DNA in the samples. The concentration of this DNA mirrors the subjective measurement of lung damage, over the same timecourse, based on inspection of the lung tissue, made for the histology report.

[0605] A significant advantage of the disclosed method, however, is that in contrast to the histology, which focused on a single tissue type, the disclosed blood-based test allows simultaneous analysis of multiple tissue and cell types for damage. As shown in Figure 10C, the inventors also detected heart tissue-derived DNA in the blood of the treated rata, and cardiotoxicity has also been reported as a complication of bleomycin treatment. Markers of other tissues, such as pancreas, however, show no significant signal over that observed in the vehicle animals (as shown in Figure 10D).

[0606] Example 9 - Preparation of Human Atlas

[0607] Tissue-specific, unmethylated DNA markers were identified using DNA extracted from eleven, healthy human cell-types (as shown in Figure 11: 1 - CD19+ B cells; 2 - CD4+ T cells; 3 - CD8+ T cells; 4 - neutrophils; 5 heart (cardiomyocytes); 6 - hepatocytes; 7 -Kupffer cells; 8 - liver endothelial cells; 9 - lung endothelial cells; 10 - lung epithelial cells; 11 - lung fibroblasts)

[0608] To identify regions specifically unmethylated in a given tissue or cell type, the inventors prepared genome-wide profiles of unmethylated DNA enriched using the disclosed platform for each of the 11 different tissue and cell types. The profile for each tissue or cell type was then compared to the profile of each of the other tissue or cell types to identify regions that were most discriminatory - i.e. those regions that were highly unmethylated in the subject tissue or cell type but highly methylated in the profiles of the other ten tissue or cell types. In this way, regions of the genome having a characteristic, highly discriminatory, methylation profile for a given tissue or cell type were identified. Typically, regions having a length of about 120-1000bp were found to be advantageous.

[0609] The hundred most discriminative regions for each individual tissue or cell type were compiled to produce the atlas shown in Figure 11, which shows the signal in the profiles of DNA extracted from three individuals (columns) for each of the atlas marker regions (rows).

[0610] As shown in Figure 11, the identified unmethylated regions are highly specific for each tissue or cell type.

[0611] Materials and Methods

[0612] A typical workflow is set out below.

[0613] In DNA samples requiring DNA fragmentation, DNA was sheared to an average of 180 bp.

[0614] A mixture of DNA (<iong), M.MpeI and ETA-AdoHCy-N3 was prepared on ice. This solution was incubated at 37 °C for 1 hour. Following incubation, the methyltransferase enzyme was inactivated by heating.

[0615] Without purification, the sample was cooled to 10°C. End Repair & A-Tailing Master Mix was added (Kapa Biosystems). The mixture was mixed thoroughly by pipette aspiration and incubated at 20°C for 30 mins followed by a 65°C incubation for a further 30 mins.

[0616] The sample was cooled to 10°C, and sequencing adapters were ligated.

[0617] Without purification, biotin-PEG4-DBCO (Jena Biosciences) was added and the mixture was incubated at 37 °C for 1 hour with shaking at 500 rpm. The DNA was subsequently purified from the reaction mixture.

[0618] 5 pL Dynabeads MyOne Streptavidin Ci beads (ThermoFisher) were washed with 150 pL of PBST. The DNA was added to the beads and the mixture was further incubated at 23 °C for 15 minutes, with shaking at 1000 rpm. Once completed, the supernatant was removed (as the “second fraction”), and the beads were washed twice with 150 pL of PBST. Finally, the bound DNA was released from the beads (as the “first fraction”) by denaturation of streptavidin.

[0619] Amplified libraries were pooled together with 0.1% PhiX and sequenced on a S4 Flow Cell using an Illumina NovaSeq Sequencer (Source Biosciences).

[0620] After sequencing, adaptors were removed from the reads using BBTools and then aligned to human reference genome HG38 using BWA-MEM2. Ambiguously alignedreads and those with low mapping scores (MAPQ score < 40) were removed using SamTools. Duplicates were removed with Sambamba (PMID: 25697820) and reads hard-clipped using jvarkit (https: / / github.com / lindenb / jvarkit). Spearman correlation plots were generated from the processed bam files with deepTools using a binsize of 1000bp and RPGC normalisation. Saturation figures and CpG density plots were generated for Chr1-22 using the QSEA and Repitools R packages. To allow direct comparison of enriched and unenriched samples, Bam files were down sampled to the same sequencing depth using SamTools. High confidence methylated and unmethylated CpG sites used for comparison were taken from the consensus of two whole genome shotgun bisulphite sequencing (WGBS) datasets performed on cell line NA12878 by the same lab (www.encodeproject.org / experiments / ENCSR890UQO / ), where less than 5% methylation in both datasets was considered to be unmethylated and greater than 95% methylation in both datasets was considered to be methylated.

Claims

Claims1. A method for identifying DNA from a specific tissue or cell type in a cell-free DNA (cfDNA) sample from a subject, the method comprising:(1) using a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag to each unmodified nucleotide residue in the sample, wherein each unmodified nucleotide residue is unmodified in the target position;(2) inactivating the methyltransferase;(3) preparing the sample into a sequencing library;(4) binding an affinity label to each tag;(5) fractionating the sequencing library to obtain a first fraction and a second fraction, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and(6) sequencing the polynucleotides of the first and / or second fraction to obtain the modification status of nucleotide residues in a target marker region of the polynucleotide sequence,wherein the target marker region of the polynucleotide sequence is a region that has a characteristic epigenetic modification pattern in the specific tissue or cell type that is indicative of the specific tissue or cell type, andwherein the detection of the characteristic epigenetic modification pattern in the modification status information identifies DNA from the specific tissue or cell type in the sample.

2. The method of claim 1, wherein the characteristic epigenetic modification pattern that is indicative of the specific tissue or cell type comprises epigenetically unmodified nucleotide residues.

3. The method of claim 1 or claim 2, wherein the method comprises sequencing the polynucleotides of the first fraction.

4. The method of any of claims 1-3, wherein obtaining the modification status of nucleotide residues in a target marker region of the polynucleotide sequence comprises comparing the sequences of the sequencing reads of the first and / or second fraction to a reference sequence comprising the target marker region to determine the location of the sequencing reads within the reference sequence and thereby the presence orotherwise of unmodified nucleotide residues at specific locations within the target marker region.

5. The method of any of claims 1-4, wherein detection of the characteristic epigenetic modification pattern in the modification status information is indicative of cell death of the identified tissue or cell type in the subject.

6. The method of claim 5, wherein the method comprises obtaining the modification status of nucleotide residues in a plurality of target marker regions of the polynucleotide sequence, and wherein:(a) the detection of the characteristic epigenetic modification pattern of a specific marker region in the modification status information indicates the presence of cell death in the specific tissue or cell type identified by the specific marker region; or(b) the detection of the characteristic epigenetic modification patterns of a plurality of marker regions in the modification status information indicates the presence of cell death in the plurality of specific tissues and / or cell types identified by the specific marker regions.

7. The method of claim 5 or claim 6, wherein the method is a method for detecting cell death in response to a specific active agent administered to the subject.

8. The method of claim 7, wherein the method further comprises comparing the level of cell death in a first cfDNA sample obtained from the subject at a first time point with the level of cell death in a second cfDNA sample obtained at a second time point, wherein:(a) the first time point is before the administration of the active agent to the subject and the second time point is after the administration of the active agent;(b) the first and second time points are after the administration of the active agent; or(c) the first time point is after a first administration of the active agent to the subject and the second time point is after a second administration of the active agent.

9. The method of claim 7 or claim 8, wherein the methyltransferase enzyme is configured to modify the cytosine of a CpG dinucleotide that is unmodified in the C5 position, andwherein the modification status is the modification status of the cytosine C5 position of CpG dinucleotides in the target marker region.

10. The method of any of claims 1-9, wherein preparing the sample into a sequencing library comprises the ligation of sequencing adapters to the polynucleotides in the sample.

11. The method of any of claims 1-10, wherein the method further comprises segregating each polynucleotide strand, after inactivating the methyltransferase and before binding an affinity label to each tag, wherein segregating each polynucleotide strand comprises performing:(i) exactly two cycles of PCR; or(ii) exactly one cycle of PCR.

12. The method of any of claims 1-11, wherein the preparation of a labelled sequencing library (steps 1-4) is performed in a one-pot approach with no intervening washing or purification steps.

13. The method of any of claims 1-12, wherein the affinity label comprises biotin and wherein fractionating the sequencing library into first and second fractions comprises fractionation using a capture agent comprising a biotin-binding protein.

14. The method of any of claims 1-13, wherein after fractionation the first and / or second fraction is amplified.

15. The method of any of claims 1-14, wherein the method is an in vitro method of diagnosing disease in a subject, the method further comprising diagnosing the disease based on the identification in the sample of DNA from the specific tissue or cell type.

16. A kit for identifying DNA from a specific tissue or cell type in a cell-free DNA(cfDNA) sample from a subject, the kit comprising:(1) a methyltransferase enzyme configured to modify a nucleotide residue in a target position to apply a tag from a cofactor analogue to each unmodified nucleotide residue in the DNA sample, wherein each unmodified nucleotide residue is unmodified in the target position;(2) an affinity label precursor suitable for binding an affinity label comprising a biotin to the tags; and(3) instructions for how the kit is to be used in accordance with the method of any of claims 1-15.